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ABSTRACT
Developing a Dissociative Nanocontainer for Peptide Drug Delivery
By
Michael Patrick Kelly

Advisor: Dr. Mandë Holford
The potency and specificity of bioactive peptides have propelled these agents to the
forefront of pharmacological research. However, delivery of peptides to their molecular
target in cells is a major obstacle to their widespread application. A Trojan Horse
strategy of packaging a bioactive peptide within a modified protein cage to protect it
during transport, and releasing it at the target site, is a promising delivery method.
Recent work has demonstrated that the viral capsid of the P22 bacteriophage can be
loaded with an arbitrary, genetically-encoded peptide, and externally decorated with a
cell-penetrating peptide, such as HIV-Tat, to translocate across in vitro and in vivo
models of the blood-brain barrier (BBB). However, disassembly of loaded capsids at the
target site remains a challenge. Here, P22-derived nanocontainer systems for controlled
disassembly and cargo release under physiological conditions are constructed,
characterized, and tested. In particular, controlled disassembly in response to two types
of bioorthogonal reactions is investigated: ring-opening metathesis polymerization
(ROMP), and bimolecular "click" conjugation. It is shown that treatment of
functionalized P22-derived nanocontainers with a water-soluble ruthenium catalyst
results in ROMP and concomitant release of a GFP reporter under physiological
conditions. In addition, genetic code expansion via amber suppression is used to
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construct self-assembling P22-derived nanocontainers that incorporate bioorthogonal
handles for inverse electron-demand Diels-Alder cycloaddition (iEDDA) and strainpromoted azide-alkyne cycloaddition (SPAAC) in a site-specific manner. Functionalized
nanocontainers are then shown to undergo morphological changes when treated with
the corresponding bioorthogonal partner under physiological conditions.
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Chapter 1: Introduction
Bioactive peptides have immense therapeutic potential, especially for the treatment of
neurological disorders and pain. Peptides are generally nontoxic, highly potent, and in
most cases extremely specific, with few side effects [1]. The first peptide to be isolated
and used therapeutically was insulin, starting in the 1920s, which was originally purified
from animal sources (and later synthesized through recombinant methods) [2]. Although
peptides continued to be used for therapeutic purposes in the succeeding decades, they
were rapidly eclipsed by small molecules [1]. Indeed, the second half of the twentieth
century is often referred to as the “chemistry era” due to the emphasis on small molecule
drugs. Today, however, the number of small molecule new chemical entities (NCEs)
approved each year by the FDA is declining, and peptides are poised for a comeback [3].
For example, Ziconotide (Prialt.), the first non-opioid analgesic, and the first peptide drug
discovered in the venom of the marine snail Conus magus, was approved by the FDA for
commercial use in 2004 [4–6]. As of 2018, there were more than 60 FDA-approved
peptide drugs on the market, with hundreds more in various stages of development [7,8].
A fundamental obstacle to the widespread use of therapeutic peptides has been their
perceived poor pharmacokinetic profile. In general, linear peptides cannot be
administered orally, do not cross the cell membrane, and are chemically unstable in vivo,
resulting in a short biological half-life [8,9]. However, there are exceptions to these
observations: a handful of structured peptides can be administered orally, many venom
peptides are stabilized by an extensive network of disulfide bonds, and specialized cellpenetrating peptides translocate across the cell membrane. There is enormous potential
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for harnessing these natural outliers to improve the pharmacokinetic profile of bioactive
peptides and thereby realize the full potential of peptide therapeutics. This thesis
addresses this challenge by examining a peptide drug delivery strategy using virus-like
nanocontainers.

1.1 Peptide-Drug Delivery using Nanocontainers.
There are several strategies for improving the pharmacokinetic profile of bioactive
peptides. One approach is to stabilize the structure of the peptide itself through such
methods as peptide stapling, macrocyclization, or grafting of peptide segments onto a
small protein scaffold [9]. However, as these methods involve changes in secondary
and tertiary structure, they may disturb the function of the peptide. In addition, these
approaches are not completely general and must be specifically adapted to each
peptide.
An alternative approach is the so-called Trojan Horse strategy, in which the peptide is
packaged within a nanoparticle carrier that can protect it during transport, and release it
upon reaching the target. The list of macromolecules that have been investigated for their
potential as delivery vectors is extensive and diverse. It includes liposomes [10], natural
and synthetic polymers [11], inorganic particles [12,13], DNA origami structures [14],
and protein cages such as ferritins and virus-like particles (VLPs) [15,16].
This thesis project focuses on nanocontainers derived from virus-like particle
(VLP) nanocontainers, specifically the T = 7 capsid of the Salmonella typhimurium
P22 bacteriophage. VLPs have a number of advantages over other macromolecules:
First, they are monodisperse in size and composition, and possess defined
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architectures—traits that can allow for precise control of pharmacological properties.
Second, as proteins, they are biodegradable by means of endogenous cellular pathways,
and thus non-toxic. Also, as gene products, VLPs can be produced relatively easily and
in high yields using standard recombinant protocols. Finally, an armamentarium of
protein engineering techniques is available for manipulating the interior and exterior of
proteinaceous VLPs.
In general, the adaptation of protein cages for drug delivery comprises three steps: 1)
encapsulation of the pharmacological agent within the viral capsid; 2) modification and
targeting of the capsid to the desired site in vivo; and 3) induced disassembly of the
capsid and release of the cargo under physiological conditions (i.e., neutral pH, moderate
temperature, and aqueous environment). A schematic overview of this process is shown
in Figure 1.1.

Figure 1.1: Schematic overview of peptide delivery by P22-derived nanocontainer. First, the peptide is
encapsulated within the nanocontainer using recombinant biology. Next, the exterior of the capsid is modified
with targeting compounds or other functional elements (shown here are norbornene, a substrate for the
biorthogonal reactions described below, and the cell-penetrating peptide HIV-Tat (YGRKKRRQRRR)).
Disassembly of the nanocontainer is triggered by a defined stimulus (here a tetrazine-comjugated moiety) and the
peptide cargo is released. The modular strategy outlined here allows for substitution of alternate conjugates, 3
alternate cargo proteins, and alternate disassembly mechanisms.

The first two steps in the adaptation of VLP nanocontainers for drug delivery—packaging
and transport—have already been worked out for P22-derived nanocontainers [17,18].
The P22 procapsid assembles from 420 copies of the P22 coat protein (CP) in the
presence of approximately 300 copies of the P22 scaffold protein (SP). SP monomers
initially remain within the capsid shell and are released at a later stage of maturation.
However, the entire SP is not needed for self-assembly: a truncated variant consisting of
residues 141-303 (SP141) is sufficient [19]. Using standard recombinant methods, the
Douglas group constructed a fusion protein consisting of an N-terminal cargo protein
joined to the C-terminal SP141 fragment by a thrombin cleavage site. When the fusion
construct was co-expressed with CP, P22 procapsids containing 200 - 300 copies of the
cargo protein were produced (Figure 1.2). This method has been used to encapsulate a
variety of gene products, including the fluorescent proteins EGFP and mCherry, the
enzyme alcohol dehydrogenase D, the CRISPR Cas9 endonuclease, and the peptide drug
ziconotide [17,18,20,21].

Figure 1.2: Packaging of a genetically programmed protein in a P22-derived nanocontainer. The P22
assembler plasmid (left) encodes the P22 coat protein and a cargo-SP141 fusion protein, which consistins of
an arbitrary cargo joined to the C-terminal domain of the P22 scaffold protein by a thrombin-cleavable
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linker. Co-expression of both proteins results P22 procapsids encapsulating 200-300 copies of the cargoSP141 fusion protein.

More recently, the Holford group devised a method for transporting loaded P22
nanocontainers across in vitro and in vivo models of the blood-brain barrier (BBB).
Briefly, the cell-penetrating peptide HIV-Tat (YGRKKRRQRRR) was synthesized,
fluorescently labeled, activated with maleimidopropionic acid (MPA), then conjugated to
a P22 nanocontainer pre-loaded with ziconotide and engineered to feature a surfaceexposed cysteine residue. P22-Tat nanocontainers translocated the BBB, demonstrating
the feasibility of this Trojan-horse strategy [18].
The third step in the adaptation of VLPs for drug delivery—namely, controllable
disassembly under physiological conditions—remains a challenge. Developing a
mechanism for inducing disassembly of P22-derived nanocontainers under
physiological conditions is the focus of this thesis project.

1.2 Induced Disassembly of P22-Derived Nanocontainers: General Strategy
As noted above, engineering the disassembly of VLP-based nanocontainers under
physiological conditions is an unsolved problem. To address the problem, this thesis
project draws upon a range of disciplines at the intersection of chemistry and biology,
with an emphasis on biorthogonal chemistry, structural virology, and protein engineering.
In particular, two classes of bioorthogonal reaction are investigated for their potential
to induce the disassembly of engineered P22 VLPs: 1) polymerization reactions, as
exemplified by ring-opening metathesis polymerization (ROMP). 2) “click”
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reactions, as exemplified by the inverse electron-demand Diels-Alder cycloaddition
(iEDDA) and strain-promoted azide-alkyne cycloaddition (SPAAC).
In the ROMP-based strategy, steric force released by the induced polymerization of
norbornene moieties attached to the capsid surface is harnessed to disrupt the capsid
architecture. Norbornene moieties are conjugated to surface-exposed lysine residues
through nonspecific bioconjugation methods. Polymerization is initiated by introduction
of a water-soluble version of the ruthenium-based Hoveyda-Grubbs catalyst (Figure
1.3A). While initial proof-of-concept experiments are performed in vitro, the catalyst
could be supplied by intravenous drip therapy for in vivo applications (see Chapter 3).

Figure 1.3: ROMP- and click-based disassembly strategies. (A) ROMP-based strategy: polymerization
of norbornene moieties conjugated to the procapsid surface pries apart the coat protein monomers. (B)
Click-based strategy (iEDDA shown here): one of the substrates of a bimolecular click reaction is
conjugated to a large scaffold, either a peptide or a PEG polymer, and conjugated to a click partner
installed at a site in the P22 coat protein (T183) associated with capsid instability.
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The click-based strategy aims to mimic an insertion mutation associated with capsid
instability. Morris and Prevelige have reported that substitution and insertion mutations at
the T183 site of the A-domain in the P22 coat protein results in capsids that are
permissive of self-assembly but thermally unstable relative to WT capsids. They reported
that manipulating this region could potentially be used “to alter the stability of the capsid
for controllable disassembly” [22]. To further explore this idea, we synthesized short
tetrazine-, norbornene-, or DBCO-conjugated peptides and PEG polymers and “click”
them to a bioorthogonal partner (norbornene, tetrazine, or azidophenylalanine,
respectively) that has been ribosomally installed at the sensitive T183 site, thus
mimicking a destabilizing insertion mutation (Figure 1.3B). The site-specific installation
of the bioorthogonal partner is accomplished through genetic code expansion using a
“hijacked” amber codon (TAG).
In short, a two-part strategy is pursued, consisting of a ROMP-based approach and a
click-based approach. Both approaches entail the construction of modified P22

Figure 1.4 Outline of Two-part Strategy for Bioorthogonal Induced Disassembly
of P22-Derived VLPs.
7

nanocontainers. Note that the click approach also requires the synthesis of engineered
“triggers.” However, both approaches have the same final goal, namely controllable
disassembly under physiological conditions. A schematic outline of this two-part strategy
is shown in Figure 1.4.
The remainder of this dissertation describes efforts to implement these strategies.
Chapter 2 reviews the biological and chemical foundations of the project, including the
structural virology of the P22 bacteriophage, bioorthogonal chemistry, and the ribosomal
incorporatiuon of noncanonical amino acids (ncAAs) in vivo through amber suppression.
In Chapter 3, the application of the ROMP-based strategy to a P22 nanocontainer is
presented. The click-based strategy is discussed in Chapter 4. Finally, future research
directions are touched on in Chapter 5. While this thesis does not resolve the delivery of
peptide therapeutics using VLPs, it significantly illuminates the challenges and potential
opportunities involved in engineering delivery systems for peptide therapeutics.
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Chapter 2: Background
2.1 Structural and Physical Virology: The Mechanics of Viral Capsids
At their core, all viruses consist of a nucleic acid genome encased and protected by a
protein coat, or capsid. Viral capsids are remarkably sophisticated structures, even in the
simplest viruses. They are monodisperse, capable of spontaneous self-assembly, and in
many cases undergo precisely choreographed conformational changes as part of a
maturation pathway. At the same time, they are resilient enough to protect the
encapsulated genome from a range of environmental challenges. In recent years,
researchers have used the findings of physical and structural virology to engineer “viruslike particles” (VLPs) or “virus-based nanoparticles” (VNPs): biocompatible protein
scaffolds with precisely defined architectures, tailored functionalities, and an expanding
suite of applications in nanomedicine and materials science.

2.1.1 Capsid symmetry and the Caspar-Klug construction
The roots of modern structural virology begin with a series of papers by Francis Crick
and James Watson, who suggested, in the mid-1950s, that viral capsids are composed of a
large number of identical small subunits packed together in a symmetrical manner. This
hypothesis was deduced from the fact—well established at the time—that for small RNA
viruses the total mass of the protein capsid far exceeds that of the viral genome. It would
seem to follow, Watson and Crick reasoned, that the genomes of these viruses do not
contain enough information to encode the protein capsid without significant redundancy
in the capsid structure. However, considerations of mathematical symmetry place
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significant constraints on the number of ways that identical subunits may be arranged to
give a spherical architecture. More specifically, the subunits are required to exhibit the
symmetry characterized by one of the three polyhedral point groups: the tetrahedral group,
the octahedral group, or the icosahedral group 1 (Figure 2.1). It would also follow, as
0F

Watson and Crick noted, that the number of subunits in a spherical virus is a multiple of

Figure 2.1: Polyhedral symmetry
groups. Tetrahedral symmetry (T,
left), octahedral symmetry (O, center,
two figures) and icosahedral symmetry
(I, right). C2 axes are indicated as
ovals, C3 axes as triangles, C4 axes as
squares, and C5 axes as pentagons.
From Voet and Voet (2011) [25].

12, since the minimum number of asymmetric units in a polyhedral point group is always
a multiple of 12 [23,24].
Within a few years, the essential accuracy of the Crick-Watson hypothesis was borne
out by X-ray diffraction and electron microscopy studies. These same studies indicated a
strong preference for icosahedral (as opposed to tetrahedral or octahedral) symmetry.
However, concurrent biochemical analyses had revealed that many icosahedral viruses
incorporate more than 60 subunits. This was puzzling, as it is mathematically impossible
to construct a spherical shell out of more than 60 identically arranged subunits (the
number of asymmetric subunits in a regular icosahedron). Caspar and Klug resolved the

1

It was known from crystallographic studies that the spherical capsids of the bushy stunt virus and the
turnip yellow mosaic virus possess cubic symmetry, meaning that the unit cell of the crystal does not have a
preferred spatial orientation. In three dimensions, there are precisely seven finite isometry groups that do
not have a preferred spatial orientation (more accurately, that have more than one axis of rotation of order 3
or more): these are the polyhedral point groups. Four of the polyhedral point groups incorporate reflections
or inversions, transformations that invert the chirality of asymmetric stereocenters. Because both proteins
and nucleic acids contain asymmetric stereocenters, these four groups are disallowed. The remaining three
point groups are the chiral tetrahedral group (T), with 12 asymmetric units; the chiral octahedral group (O),
with 24 asymmetric units; and the chiral icosahedral group (I), with 60 asymmetric units [24,26].
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problem in 1962 with their theory of quasi-equivalence, now known as the Caspar-Klug
(CK) construction [26].
Caspar and Klug pointed out that more than 60 subunits could be accommodated by
regarding spherical capsids as having icosadeltahedral (rather than icosahedral) symmetry.
Icosadeltahedra can be regarded as “expanded” icosahedra in which hexavalent positions
are symmetrically intercalated between the 12 pentavalent vertices (Figure 2.2). They
represent a more general class of polyhedra that includes the regular icosahedron as a
special case. (The icosahedron is an icosadeltahedron for which the number of incalated
hexavalent positions is zero.) In addition to allowing for more than 60 subunits, the CK
construction relaxes the requirement that the asymmetric subunits occupy strictly
identical environments (except in the special case of the regular icosahedron). Subunits
are quasi-equivalent rather than strictly equivalent: small deviations from strict
equivalence are permitted so long as they are energetically favorable [26].
Icosadeltahedra are characterized by a pair of integers (h,k) that specify the relative

Figure 2.2: The CK Construction. (A) A representative model of a CK structure showing three color-coded
quasi-equivalent positions, each of which corresponds to a protein monomer. The pentavalent positions are
indicated in blue, while the hexavalent positions are shown in alternating green and red. (B) Wireframe models of
CK structures exhibiting icosadeltahedral symmetry. Pentavalent vertices that correspond to the underlying
icosahedral symmetry are outlined in red. The intercalated hexavalent positions are outlined in black. Note that
each pentavalent frame incorporates five protein monomers, while each hexavalent frame incorporates six
monomers. This may be seen by comparing the (1,1) structure second from left in (B) with the model in (A) to
which it corresponds. The special case of the regular icosaderon (actually its dual, the regular dodecahedron),
which lacks hexavalent positions, is shown at far left. The (h,k) designation for each construction is indicated (see
text and legend to Figure 2.3 for details). From Šiber (2007).
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positions of adjacent pentavalent vertices against a hexagonal lattice background. The
number of quasi-equivalent positions in an (h,k) icosadeltahedron is given by 𝑇 = ℎ! +
ℎ𝑘 + 𝑘 ! , also known as the “triangulation number” or “T-number.” T-numbers are
ubiquitous in structural virology, and are commonly used to classify viral particles. They
also yield formulae for the number of protein monomers in a viral capsid, Nmonomer = 60T,
the number of hexamers, Nhexamer = 10(T - 1), and the number of capsomeres, Ncapsomere =
10T + 2 [27,28].

Figure 2.3: T-numbers and the classification of icosahedral capsids. The T-number provides a useful classification system for
icosahedral capsids. It may be understood through the examination of mappings from a flat hexagonal lattice onto the surface of a
regular icosahedon. First note first that a flat hexagon may be converted into a “domed” pentagon structure by removing a triangle
wedge and gluing the free edges together (A). Similarly, a flat net of 20 equilateral triangles may be folded up into a regular
icosahedron. If the triangle net is now superimposed on a hexagonal lattice in such a way that each triangle vertex coincides with
the center of a lattice hexagon, we obtain a template for a mapping from the hexagon lattice (with the appropriate triangle wedges
removed) to the icosahedron surface (B). Note, however, that it is not necessary for the proto-fivefold hexagons (i.e., the hexagons
that are cut and folded up into fivefold vertices) to be directly adjacent in the lattice. We only require that they be symmetrically
disposed. Because the lattice is two-dimensional and each triangle vertex coincides with the center of a lattice hexagon, the relative
position of neighboring proto-fivefold hexagons (or equivalently, vertices in the triangle net) may be indexed by a pair of integers
(h,k) representing steps in terms of the lattice basis vectors â1 and â2 (C). Thus the vector A(h,k) connecting any two neighboring
proto-fivefold hexagons consists of h steps in the â1 direction followed by k steps in the â2 direction, A(h, k) = hâ1 + kâ2. The
triangulation number is defined as the square of the magnitude of this vector, T = |A(h,k)|2. It may also be expressed, using basic
trigonometry, as T = h2 + hk + k2. It should be noted that the polyhedron constructed through this procedure is chiral when and , so
that the (1,2) and (2,1) polyhedra, for example, are mirror-images. Chiral variants are distinguished as dextro (D) or laevo (L).
From Šiber (2007) and Bruinsma and Klug (2015).
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2.1.2 Continuum Models
By regarding the viral capsid as an icosadeltahedral arrangement of identical small
subunits, the CK construction emphasizes its discrete nature. A complementary approach
to the study of capsid structure uses the tools of continuum mechanics, specifically the
theory of elasticity, to model the capsid as a homogeneous thin elastic shell. While the
continuum model gives the best approximation for large viruses with many subunits, it
provides insight into the behavior of smaller capsids as well [29,30].
The continuum analysis of capsid mechanics posits a thin elastic shell of radius R and
thickness h, where “thin” here means that ℎ ≪ 𝑅. From continuum theory, the elastic
energy 𝐸! of a deformed shell can be decomposed into an out-of-plane bending
component 𝐸! and an in-plane stretching component 𝐸! [29]:
𝐸! = 𝐸! + 𝐸! . #(1)
For a thin shell, the out-of-plane bending energy is described locally by [31]
𝑑𝐸! =

𝜅
2𝐻 − 𝑐!
2

!

+ 𝜅! 𝐾 𝑑𝑆#(2)

where 𝐻 = 1 2(1 𝑅! + 1 𝑅! ) is the mean curvature of the surface (𝑅! and 𝑅! are the
principal radii of curvature), 𝑐! is the spontaneous shell curvature, 𝜅 is the bending
rigidity, 𝜅! is the Gaussian rigidity, and 𝐾 = 1 (𝑅! 𝑅! ) is the Gaussian curvature. The
[𝜅 2(2𝐻 − 𝑐! )! ] 𝑑𝑆 term accounts for the energy density due to displacement from the
mean curvature 𝑐! of the shell at equilibrium. (It is analogous to the potential energy of a
harmonic oscillator 𝐸!" = 𝑘 2 (𝑥 − 𝑥! )! , where x0 is the equilibrium position and x is
the displacement.) The second term, 𝜅! 𝐾𝑑𝑆, is the energy density that results from the
intrinsic curvature of the shell. To obtain the total bending energy, we simply integrate
over the entire surface:
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𝐸! =

𝜅
2𝐻 − 𝑐!
2

!

+ 𝜅! 𝐾 𝑑𝑆. # 3

Because the Gaussian curvature integrates to a constant over a surface with a fixed
topology, 2 the second term is often discarded in situations where the shell is not ripped or
1F

torn [28,29]. The contribution from the in-plane stretching energy may be treated in
similar fashion. The stretching energy density is described by
𝑑𝐸! =

1 !
!
𝜆𝜀 + 𝜇𝜀!"
𝑑𝑆# 4
2 !!

where 𝜀!" is the strain tensor and 𝜆 and 𝜇 are the first and second Lamé coefficients
!
(which quantify the elastic properties of a material) [29]. The 𝜀!!
term accounts for
!
energy due to the expansion or compression of the shell material, while the 𝜇𝜀!"
term

accounts (indirectly) for energy from shearing forces. Once again, the total stretching
energy is obtained by integrating over the entire surface:
𝐸! =

1 !
!
𝜆𝜀 + 𝜇𝜀!"
𝑑𝑆. # 5
2 !!

As noted above, the total elastic energy is the sum of the stretching and bending energies:
𝐸! =

𝜅
2𝐻 − 𝑐!
2

!

1 !
!
+ 𝜅! 𝐾 + 𝜆𝜀!!
+ 𝜀!"
𝑑𝑆. # 6
2

In 2003, Lidmar, Mirny and Nelson (LMN) applied the elastic shell model to the CK
construction to examine the behavior of elastic icosahedral shells in the 𝑇 ⟶ ∞ limit
[28]. Icosahedra were modeled as elastic shells with spherical topology and 12 fivefold
2

The Gauss-Bonnet theorem from differential geometry states that ! 𝐾𝑑𝐴 + !" 𝑘! 𝑑𝑠 = 2𝜋𝜒(𝑀), where
M is a compact two-dimensional Riemannian manifold with boundary 𝜕𝑀, 𝑘! is the geodesic curvature of
𝜕𝑀, and 𝜒(𝑀) is the Euler characteristic of M. For a closed manifold, the boundary 𝜕𝑀 vanishes, so this
reduces to ! 𝐾𝑑𝐴 = 2𝜋𝜒(𝑀). Because the Euler characteristic is a topological invariant, it is constant
over a surface with a fixed topology, i.e., so long as the shell is not punctured or torn. It follows that the
integral on the left is constant as well. Incidentally, the Euler characteristic of any surface that is
!
homeomorphic to a sphere is two, so we conclude that for a spherical shell, 𝐸! =
𝜅 𝐻 − 𝑐! ! 𝑑𝑆 +
!
4𝜋𝜅! .
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disclinations (topological defects) corresponding to the fivefold vertices of a regular
icosahedron. From previous studies it was known that an isolated disclination in a flat
triangular lattice results in a buckling transition for 𝑌 𝑅

!

𝜅 ≥ 154, where 𝑅

!

is the

average radius of the flat triangular lattice, 𝑌 is the 2D Young’s modulus (which
quantifies the “stiffness” of a material and can be directly related to the Lamé
coefficients) 3, and κ is the bending rigidity introduced above in equation (2) (Figure 2.4).
2F

Lidmar et al. demonstrated that a similar buckling transition occurs for elastic icosahedral
shells, at similar values of 𝛾 = 𝑌 𝑅

!

𝜅. In fact, the total energy of an elastic icosahedral

shell depends only on the value of 𝛾, a dimensionless quantity known as the Föppl-von
Kármán (FvK) number. The FvK number essentially measures the ratio of stretching to
bending stiffness [29,32]. The existence of a buckling transition directly proportional to
𝑅

!

accounts for the observation that large capsids tend to be angular and faceted, while

Figure 2.4: Triangual lattices with pentavalent disclinations. The lattice is flat for FvK values of (A), but
undergoes a buckling transition and assumes a conical morphology for (B). The fivefold disclination is circled in
red. (C) Representations of T = 12 (upper left), T = 40 (upper right), T = 84 (lower left), and T = 144 (lower right)
icosadeltahedra show increased faceting as . From Lidmar, Mirny and Nelson (2003).

3

The 2D Young’s modulus Y and the Poisson ratio ν, which quantifies the extent to which a material
expands laterally when compressed, may be related to the Lamé coefficients λ and µ by 𝜆 = 𝑌 (1 − 𝜈 ! )
and 𝜇 = 𝑌 2(1 + 𝜈) [28].
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small capids tend to be spherical [28].
The continuum elastic model has also been used to study the response of viral shells
to a radial force, such as that applied by the probe of an atomic force microscope (AFM).
In particular, the theory of elastic thin shells predicts that an infinitesimal point force F
will produce a dimple[32] with indentation 𝜁 such that 𝜁(𝐹) ∝ 𝐹𝑅

𝜅𝑌, where κ, Y, and

R are defined as above [33]. Rearranging, we have 𝐹 ∝ 𝜁(𝐹) 𝜅𝑌 𝑅 or, because κ, Y, and
R are constants, 𝜁(𝐹) ∝ 𝐹. In other words, the relationship between force and
displacement is linear for small indentations, and the shell behaves like a harmonic
oscillator. This prediction has been experimentally verified through AFM
nanoindentation studies, which make it possible to quantify the relationship between F
and 𝜁. In fact, with many viral capsids force deformation curves show approximately
linear behavior for 𝜁 < ~0.6𝑅. Beyond this point, the shell undergoes catastrophic
structural failure [32,34] (Figure 2.5).

Figure 2.5: Schematic illustration of
an AFM nanoindentation
experiment. The probe comes into
contact with the capsid shell at 0 nm.
Initially, in the reversible indentation
regime, the relationship between force
and indentation is linear. At an
indentation of ~10 nm, the capsid
undergoes structural failure, resulting
in a discontinuity in the force
deformation curve. From Roos et al.
(2010).
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2.2 Bacteriophage P22
Bacteriophage P22 is a temperate phage that belongs to the Podoviridae family and
infects Salmonella enterica serovar typhimurium [35]. It has a 43.5 kbp dsDNA genome
that is packaged into a T = 7L capsid via a headful mechanism [36]. P22 has been studied
extensively since the 1950s, when it played a key role in the discovery of generalized
transduction by Zinder and Lederberg [37]. In recent years, the capsid has been
investigated for its potential as a protein scaffold in a range of biotechnological
applications, including materials science and nanomedicine [17,18,21,38].
The P22 life cycle resembles that of other temperate dsDNA phages. Infection
commences when the virion adsorbs to its primary receptor, the O-antigen of
lipopolysaccharide (LPS) on the outer membrane of S. enterica [39]. Contact with the Oantigen triggers slow ejection of the 43.5 kbp genome in vitro and is thought to serve the
same function in vivo [40,41]. The host membrane protein OmpA, which accelerates
DNA ejection in vitro, appears to function as a secondary receptor [36]. After delivery of
the phage genome into the host cytoplasm, the bacteriophage either enters the lytic
pathway or integrates into the host chromosome as a prophage. In the lytic pathway, the
genome circularizes by recombination and immediately begins replication by the rollingcircle mechanism. After about 1 hour, the host cell is lysed and 300-500 phage virions are
released [42].
The assembly and maturation of the infectious virion is a multistage process (Figure
2.6). It begins with the formation of a procapsid intermediate, a 50nm T = 7L shell
composed of 415 copies of the 46.5 kDa coat protein (gp5) and a dodecameric portal
complex (gp1). Assembly of the procapsid is guided by approximately 300 copies of the
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scaffold protein (gp8), which remain inside the protein shell together with 12 – 20 copies
of the pilot and ejection proteins (gp7, gp16, and gp 20) [43]. DNA packaging occurs
when the terminase complex (gp2, gp3) binds to the end of the dsDNA genome and loads
it into the procapsid through the portal channel in an ATP-dependent process [44].
Packaging results in the expansion of the procapsid to a faceted, highly stable 65nm
particle (the “expanded conformation”), and is accompanied by the expulsion of the
scaffold proteins through ~18 x 24 Å pores in the hexameric capsomeres [45]. Maturation
concludes with portal closure by three minor proteins (gp4, gp10, and gp26) and addition
of the tailspike (gp9).

Figure 2.6: Assembly and maturation of the P22 bacteriophage. From
Prevelige and Fane in Viral Molecular Machines (2012).

As noted above, noninfectious virus-like particles (VLPs) can be derived from the
capsid of the P22 bacteriophage. These P22-like VLPs are produced by the heterologous
co-expression in E. coli of the coat protein and scaffold protein. They are composed of
420 (rather than 415) coat protein monomers, since they lack the dodecameric portal
complex that replaces one of the fivefold vertex positions in the infectious virion.
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Interestingly, the expansion that accompanies DNA packaging can be mimicked in vitro
by heating the VLPs at 65°C. Heating at 75°C induces release of the pentons from the
fivefold vertices, resulting in the so-called wiffle-ball conformation. Heating at more than
80°C results in complete dissociation of the capsid. The procapsid, expanded, and wiffleball conformations can be distinguished by native agarose electrophoresis [35,46,47].
The Douglas group has adapted P22-derived VLPs as platforms for the encapsulation
of genetically programmed protein cargoes. This programmable cargo system makes use
of the finding that the complete wild-type scaffold protein is not needed for capsid selfassembly; the C-terminal alone is sufficient. In particular, deletion of 140 residues from
the N-terminal of the scaffold protein results in a truncated mutant that retained its
assembly-promoting function [19]. The Douglas group used this property to engineer
cargo-scaffold fusion proteins in which the N-terminal cargo protein and the C-terminal
scaffold protein fragment (SP141) are joined by a cleavable linker. When co-expressed
with the P22 coat protein, the cargo-SP141 fusion is loaded into self-assembling VLPs,
with 200-300 fusion proteins per capsid [17].

Figure 2.7: The P22 procapsid intermediate (A), mature virion (B) and coat protein (C). The fivefold
icosahedral vertices are visible in red in (A) and (B). Note that the procapsid is approximately spherical, while
the mature virion is more faceted. Images generated from Protein Data Bank (PDB) 2XYZ and 2XYY. In silico
Cα-backbone model of residues 10-425 of the P22 bacteriophage coat protein monomer. The A-domain is one of
eight domains in the P22 coat protein (C), the others being the extra-density (ED) domain, E loop, D loop, F
loop, P domain, N arm, and a long helix. From Chen, et al., (2011).

19

The ongoing investigation of P22 structure and morphology continues to yield
insights with potential applications to biomedicine. In 2014, the Prevelige group reported
that insertions at residue T183, which is located in an unstructured solvent-exposed loop
in the A-domain of the P22 coat protein, resulted in capsids that are capable of selfassembly yet temperature-sensitive. (The distinction is important in that many coat
protein mutations abolish self-assembly altogether). In particular, it was observed that the
T183GGGRGDGGG mutation resulted in procapsids that exhibited increased activation
energy for transition to the expanded conformation, that did not assume the wiffle-ball
conformation, and that dissociated at lower temperatures relative to wild-type. Moreover,
the T183AAA mutation produced a temperature-sensitive phenotype in infectious phage.
These findings indicated that rearrangement of the A-domain loop containing T183 is
crucial for transition to the expanded conformation of the mature capsid (Figure 2.8).
They also suggested the possibility of tuning the stability of the procapsid through
targeted manipulation of the T183 site [35].

Figure 2.8: Reorganization of the A-domain during capsid maturation. The A-domain, shown in
orange, undergoes significant conformational change during maturation from the procapsid
intermediate (left) and the mature virion (right). From Chen et al., 2011.
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2.3 Bioorthogonal Reactions
Bioorthogonal reactions are reactions that take place under physiological conditions and
do not interfere with endogenous biological processes. Sletten and Bartozzi define a
bioorthogonal reaction as one in which the participating functional groups are (i) inert to
biological moieties, (ii) selectively react with each other under biocompatible conditions,
and (iii) are nontoxic to cells and organisms [48]. In addition, it is useful if one or more
of the participating functional groups is small, as small substrates are less likely to
perturb native biological function; if yields are quantitative or near-quantitative; if the
substrates are relatively stable in biological environments; and if the reaction functions at
low concentrations [49]. Finally, the ideal bioorthogonal reaction will possess fast
kinetics in order to compete with endogenous enzymatic processes. In practice, this
would mean second-order rate constants of 104 M-1 s-1 or higher, since most enzymatic
reactions have second-order rate constants in the neighborhood of 103 – 106 M-1 s-1, and
some, such as carbonic anhydrase, (k ~ 1 x 1010 M-1 s-1), operate at or near the diffusioncontrolled limit [50–52]. While most studies of bioorthogonal reactions over the last two
decades have focused on bimolecular ligations (“click reactions”), other types of reaction,
such as the ring-opening metathesis polymerization (ROMP) employed in this thesis
project and discussed in detail below, may be considered bioorthogonal as well.

2.3.1 The Staudinger Ligation and Traceless Staudinger Ligation
Among the first bioorthogonal reactions to be investigated was the Staudinger ligation, a
variant of the Staudinger reduction studied by Hermann Staudinger at the beginning of
the twentieth century. The Staudinger reduction is a two-step reaction whereby a

21

triphenyl phosphine and an azide react to form a phosphine oxide and an amine (Figure
2.9A). In the first step, an aza-ylide is formed with the expulsion of dinitrogen. In the
presence of water, the aza-ylide is then hydrolyzed to the amine and the phosphine oxide.
By creating an electrophilic trap in the form of a methyl ester, the Bertozzi group was
able to arrest the Staudinger reduction after the first step to produce a stable covalent
adduct (Figure 2.9B) [49]. Soon after, the same group reported a “traceless” Staudinger
ligation in which the phosphine oxide is released from the final product, leaving behind
only an amide bond (Figure 2.9C) [53]. One drawback of the Staudinger ligation and its
variants is that it is relatively sluggish, with second-order rate constants around 1 x 10-3
M-1 s-1. Another is that the phosphine reactant is subject to oxidation under physiological
conditions, which necessitates relatively high concentrations of this substrate [54].

Figure 2.9: Staudinger Reactions. (A) The Staudinger reduction. (B) The Staudinger ligation. (C) The
traceless Staudinger ligation.
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2.3.2 Copper(I)-Catalyzed Azide-Alkyne Cycloaddition: “The Click Reaction”
The archetypal bioorthogonal click reaction is the Cu-catalyzed azide-alkyne
cycloaddition (CuAAC) discovered by Sharpless and Meldal in 2002 [55,56]. CuAAC is
a variant of the 1,3-dipolar cycloadditions investigated by Rolf Huisgen in the midtwentieth century. In the original reaction, which takes place at high temperature
(~100°C) or high pressure, an azide and an alkyne undergo [3 + 2] cycloaddition to afford
stable 1,2,3-triazole adducts of both the 1,4- and 1,5-isomers [57,58]. Sharpless and
Meldal discovered that the azide-alkyne cycloaddition can be carried out under
physiological conditions in the presence of copper(I) salts. The reaction is moderately
fast, with second-order rate constants in the 101 – 102 M-1 s-1 range, and affords only the
1,4-isomer (Figure 2.10) [59]. However, the Cu(I) salts that catalyze the reaction also
generate cytotoxic reactive oxygen species (ROS) [60].

Figure 2.10: The Huisgen 1,3-dipolar cycloaddition and copper-catalyzed azide-alkyne cycloaddition
(CuAAC).
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2.3.3 Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC)
There are several strategies for circumventing the issue of copper(I) cytotoxicity. One is
through the use of water-soluble copper ligands or copper-chelating azides [54]. An
alternative approach is to do away with the copper catalyst altogether. This was
accomplished by Bertozzi and co-workers by incorporating the alkyne into a cyclooctyne
moiety, introducing ring-strain into the alkyne and thus activating it for [3 + 2]
cycloaddition with azides. The resulting catalyst-free reaction is known as the strainpromoted [3 + 2] azide-alkyne cycloaddition (SPAAC). The reactivity of the alkyne may
be further enhanced through the introduction of electron-withdrawing substituents (such
as fluorine) at the propargylic position, or by increasing the ring-strain through the
addition of benzyl groups [61] (Figure 2.11). SPAAC is considerably slower than the
CuAAC reaction, with second-order rate constants in the 10-2 – 101 M-1 s-1 range [62].
Nevertheless, it is reliable, and furnishes an excellent starting point for code expansion

Figure 2.11: Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC). (A) The SPAAC reaction.
(B) Enhanced cyclooctyne reagents for SPAAC, from left: cyclopropene, norbornene, transcyclooctene (TCO), and strained trans-cyclooctene (sTCO).
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experiments, given the robustness of the MjTyrRS/tRNACUA system used for genetic
incorporation of azidophenylalanine (see below) and the commercial availability of both
azidophenylalanine and DBCO.

2.3.4 Inverse Electron-Demand Diels-Alder Cycloaddition (iEDDA)
The inverse electron-demand Diels-Alder cycloaddition is related to the Diels-Alder
reaction studied by Otto Diels and Kurt Alder in the 1920s, ad familiar to generations of
students from introductory organic chemistry. However, while the Diels-Alder reaction is
a [4 + 2] cycloaddition between an electron-rich diene and an electron-poor dienophile,
iEDDA is a [4 + 2] cycloaddition between an electron-poor diene and an electron-rich
dienophile. In a biological context, the most common reactants in iEDDA are 1,2,4,5tetrazines (electron-poor dienes) and strained cycloalkenes (electron-rich dienophiles)
such as norbornenes, cyclopropenes, bicyclononynes, and trans-cyclooctenes (TCOs).

Figure 2.12: The Inverse Eletron-Demand Diels-Alder Cycloaddition (iEDDA). (A) Mechanism of
the iEDDA reaction. (B) Dienophiles used in iEDDA, from left to right: cyclopropane, norbornene,
trans-cyclooctene (TCO), cyclopropane-fused trans-cyclooctene (sTCO).
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The reaction proceeds through the formation of a highly strained bicyclic intermediate
that subsequently expels dinitrogen to yield a 4,5-dihydropyridazine product, which
isomerizes to the 1,4-dihydropyridazine product in protic solvents (Figure 2.12) [63].
Crucially, the iEDDA reaction is catalyst-free and proceeds in aqueous media—in
fact, the reaction is accelerated in water, probably due to a stabilized transition state and
hydrophobic interactions between the diene and the dienophile [64]. The primary
determinant of reaction kinetics is the energy difference between the HOMO of the
dienophile and the LUMO of the diene. As a result, the kinetics may be fine-tuned by
altering the electron-withdrawing substituents on the tetrazine or by adjusting the amount
of ring-strain on the strained alkene. Moreover, both tetrazines and strained alkenes have
been site-specifically incorporated into proteins through genetic code expansion (see
below). Second-order rate constants for genetically encoded substrates vary considerably
depending on the specific reactants, but can be very fast, from 1 M-1 s-1 for reactions
between a genetically encoded norbornene and a dipyridyl tetrazine probe to 9 x 104 M-1
s-1 for reactions between a genetically encoded tetrazine and a strained trans-cyclooctene
(sTCO) probe (Figure 2.11B) [50,65].
2.3.4 Olefin Metathesis: Ring-Opening Metathesis Polymerization (ROMP)
Olefin metathesis refers to the metalcatalyzed reassortment of carboncarbon double bonds between olefin
(i.e., alkene) substrates, as illustrated
in Figure 2.13. Although these
reactions were discovered in the 1950s,

Figure 2.13: General scheme of olefin metathesis
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it is only in the last three decades that olefin metathesis has developed into a mature
technology, resulting in the 2005 Nobel Prize for Richard R. Schrock, Robert H. Grubbs,
and Yves Chauvin.
The design and development of olefin metathesis catalysts has been an especially
productive line of research. In general, the compounds that catalyze olefin metathesis are
transition metal complexes. In the 1970s and 1980s, researchers investigated numerous
transition metals for their catalytic properties. Tungsten, molybdenum, titanium, and
tantalum complexes were all found to catalyze the metathesis reaction, in many cases
with high activity. However, these complexes were not selective for olefins and either
reacted with or were inhibited by other functionalities, whether on the substrate itself or
in the bulk solvent. A breakthrough came in the late 1980s when it was discovered that
ruthenium alkylidene complexes (L2X2Ru=CHR) reacted preferentially with olefins even
in the presence of aldehydes, alcohols, and water [66].
Today, ruthenium catalysts that are broadly compatible with a range of functional
groups, including esters, amides, ketones, aldehydes, alcohols, and water, are
commercially available. Chiral catalysts, immobilized catalysts, catalysts with tailored
initiation or propagation rates, water-soluble catalysts, and photo-activated catalysts are
also being intensively developed [67–70]. As might be expected given the ubiquity of the
carbon-carbon bond and the accessibility and versatility of ruthenium catalysts,
ruthenium-catalyzed olefin metathesis has found numerous applications, ranging from
polymer chemistry and natural product synthesis to industrial chemistry, green chemistry
and, increasingly, chemical biology [71,72].
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Three broad classes of olefin metathesis reaction are illustrated in Figure 2.14. In
ring-opening metathesis (ROM), a cyclic olefin reacts with a linear olefin to generate an
acyclic diene. A special case of ROM is ring-opening metathesis polymerization (ROMP),
in which the release of ring strain in a cyclic olefin monomer drives a chain-growth
polymerization reaction. (It is the ROMP of norbornene monomers with which we are
concerned in this thesis project.) A second class of metathesis reaction is ring-closing
metathesis (RCM), which involves the closure of an acyclic diene, with the expulsion of

Figure 2.14: Categories of olefin metathesis.

ethylene, to form a cyclic alkene. At high substrate concentrations, the diene is induced to
react with itself, resulting in acyclic diene metathesis polymerization (ADMET), a chaingrowth polymerization reaction similar to ROMP. Finally, cross-metathesis (CM) swaps
the carbon atoms of two linear alkene fragments. In practice CM is often used to form
carbon-carbon double bonds, again with the release of ethylene.
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The mechanism of olefin metathesis was first described by Yves Chauvin in 1971 and
confirmed by a series of experiments beginning in the mid-1970s [73,74]. It starts with
the reversible dissociation of the phosphine ligand to form an active catalytic complex.
The active complex can then either re-associate with the phosphine or reversibly
coordinate with an olefinic substrate. Reversible formation of a metallacyclobutane
intermediate follows via a [2 + 2] cycloaddition. The metallacyclobutane subsequently
undergoes scission via a [2 + 2] cycloreversion, affording either the original reactants or,
in the case that the bonds that are broken are not the same as the bonds that were formed,

Figure 2.15: Mechanism of olefin metathesis

novel products. This scheme is illustrated in Figure 2.15. In the context of
polymerization reactions such as ROMP, a distinction is often made between the rate
constant of initial phosphine dissociation (“initiation rate”) and the net rate constant of
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the remaining steps in the cycle (“propagation rate”). The polydispersity of the polymer
product is a function of the ratio between the initiation rate and the propagation rate.
While ruthenium catalysts are tolerant of water and other protic solvents,
conventional catalysts such as the first- and second-generation Grubbs catalyst and the
Hoveyda-Grubbs catalyst (Figure 2.16) are minimally soluble in water. In the context of
natural product synthesis or polymer chemistry, olefin metathesis is typically carried out
in dry, degassed solvents such as dichloromethane. For many years, the usual method of
performing olefin metathesis in water was through the use of aqueous emulsions or
mixtures of organic solvents and water [75,76]. However, in 2006 Grubbs and coworkers developed a number of water-soluble variants of the first- and second-generation
Grubbs catalyst and the Hoveyda-Grubbs catalyst by attaching hydrophilic tags such as
quaternary ammonium groups or poly(ethylene glycol) (PEG) to the catalyst itself [77].
This approach was further developed by Grela et al., who succeeded in attaching a
quaternary ammonium group to the N-heterocyclic carbene (NHC) ligand of the
Hoveyda-Grubbs catalyst. This water-soluble version of the Hoveyda-Grubbs catalyst is
commercially available under the trade name “AquaMet” [78] (Figure 3.6, below).

Figure 2.16: Commercially available ruthenium catalysts. (A) Grubbs catalyst 1st
Generation (B) Grubbs Catalyst 2nd Generation and (C) Hoveyda-Grubbs Catalyst 2nd
Generation
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The selectivity and water-tolerance of ruthenium catalysts has stimulated research
into applications of olefin metathesis in a biological context. Much of this work has
focused on the design and construction of a synthetic enzyme to catalyze metathesis in
vivo. A breakthrough was achieved by the Ward group in 2016 using a biotinylated
version of the second generation Hoveyda-Grubbs catalyst as an organometallic cofactor
and streptavidin as a protein scaffold. Treatment of an E. coli strain engineered to secrete
streptavidin into the periplasm with the biotinylated ruthenium cofactor resulted in the in
situ assembly of a functional in vivo synthetic metathase (Figure 2.17). Saturation
mutagenesis was then used to create libraries of streptavidin binding-pocket mutants, and
clones were screened for increased metathase activity and substrate specificity. The
evolved mutants were found to catalyze olefin metathesis in live cells, with activities that
compared favorably with commercial catalysts. Mutants also exhibited a degree of
tunable substrate specificity. In addition to the exciting implications for the development
of synthetic metabolic pathways, these findings demonstrated that ruthenium-catalyzed
olefin metathesis is a viable bioorthogonal reaction for in vivo applications [79].

Figure 2.17: Schematic overview of the design and construction of an artificial
metalloenzyme for in vivo metathesis. From Jeschek et al. (2016).
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2.4 Noncanonical Amino Acid (ncAA) Mutagenesis.
The standard genetic code is the set of rules by which triplet codons of the four canonical
nucleotides are translated into an alphabet of 20 proteinogenic amino acids (Figure 2.18).
The genetic code is near-universal—indeed, until the mid-1980s it was widely believed
that it was universal. However, researchers have since compiled a growing list of
exceptions. Isolated codon reassignments have been identified in yeast, in ciliates, and in
bacteria, and significant deviations from the standard code have been reported in
mitochondrial genomes under high selective pressure. In addition, selenocysteine and
pyrrolysine—the “twenty-first” and “twenty-second” amino acids, respectively—are
ribosomally incorporated in some instances. The evidence thus suggests that if the
genetic code is a “frozen accident,” as Francis Crick once described it, it is not so much a
deep-frozen accident as a slushy one [80–86].

Figure 2.18: The Standard Genetic Code
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At the same time, modified proteins and proteins that depend on functional groups
beyond those of the 20 canonical amino acids are ubiquitous in biology. These range
from the selenocysteine and pyrrolysine residues mentioned above, to nonribosomal
peptides that incorporate N-methylated and D-amino amino acids, to enzymes that
employ metal cofactors to the dizzying array of post-translational modifications that play
such a crucial role in signal transduction and cell-trafficking. It seems clear that the 20
canonical amino acids, despite their flexibility and adaptability, do not exhaust the space
of protein functionality.
Over the last two decades, protein engineers and chemical biologists have explored
that space by expanding the genetic code to accommodate nancanonical amino acids. In
the most common approach, the amber stop codon (TAG) is “hijacked” and reassigned to
code for a 21st amino acid by means of a modified (orthogonal) tRNA and a modified
(orthogonal) aminoacyl-tRNA synthetase (the enzyme that aminoacylates the 5’-CCA-3’
acceptor stem of a cognate tRNA with a dedicated amino acid). The orthogonal tRNA
then enters the A site of the ribosome and is incorporated into the nascent peptide
(Figure 2.19). This method has allowed researchers to create proteins with enhanced

Figure 2.19: Cellular Incorporation of a noncanonical amino acid via amber suppression. An
orthogonal tRNA (o-tRNA) is specifically aminoacylated with a dedicated noncanonical amino acid by
its cognate orthogonal tRNA-synthetase. The charged o-tRNAncAA then enters the A site of the
ribosome and the ncAA is incorporated into the nascent peptide. Adapted from Lang and Chin (2014).
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properties and novel chemistries. In the context of bioconjugation, it has allowed for
exquisite control over the stoichiometry and chemoselectivity of the conjugation process.
While noncanonical proteins can also be synthesized using chemical methods such as
solid-phase peptide synthesis and native chemical ligation, these approaches are more
suited to small peptides, as yields decrease significantly with increasing peptide length. In
any case it is difficult to compete with the synthetic prowess of the ribosome, which in E.
coli catalyzes the template-encoded polymerization of 20 amino acids per second with an
error rate of approximately 10-4 per residue [87]. Finally, in vivo code expansion can be
used in concert with other cell-based engineering methods such as recombinant
expression and directed evolution.

2.4.1 Ribosomal Incorporation of Noncanonical Amino Acids
There are two common methods for the ribosomal incorporation of noncanonical amino
acids in living organisms: global suppression (also known as selective pressure
incorporation), and nonsense or frameshift suppression. Reconstituted in vitro systems
have also been reported. For an illuminating discussion of one such system, see
Murakami, Ohta, et al. (2006) and Passioura and Suga (2017) [88,89].

2.4.1.1 Global Suppression. Global suppression is the replacement of one of the 20

canonical amino acids with a noncanonical analog. It was first reported in the 1950s by
Cowie and Cohen, who demonstrated the substitution of selenomethionine for methionine
in E. coli [Cowie and Cohen, 1957]. Global suppression is typically carried out using an
auxotrophic strain, i.e., a strain that lacks the machinery for the biosynthesis of a
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particular amino acid. Cells are grown to high density in a medium that contains all 20
amino acids, then switched to a defined medium in which the missing amino acid—most
commonly methionine—has been replaced with a ncAA analog. From this point forward,
the ncAA is incorporated throughout the proteome. An important consideration is that the
ncAA analog must be recognized by the endogenous aminoacyl-RNA synthetase (RS)
that incorporates the missing amino acid. This necessarily limits the range of amino acids
that may be incorporated by this method, though the palette may be expanded by cotransformation with a mutant RS [90,91] Finally, because the ncAA is incorporated
throughout the proteome, global suppression can result in growth defects and reduced
protein yields.

2.4.1.2 Site-Specific Incorporation: Nonsense and Frameshift Suppression. The site-specific

incorporation of noncanonical amino acids requires three components: (1) a noncanonical
amino acid (ncAA), (2) a reassigned or blank codon, and (3) an orthogonal aminoacyltRNA synthetase/tRNA (o-aaRS/tRNA) pair. These components are discussed in more
detail directly below. When all three components are in place, the endogenous translation
machinery incorporates the ncAA into a nascent peptide whenever it encounters the
reassigned codon in an mRNA template.
2.4.1.2.1 Noncanonical Amino Acids (ncAAs)

By one recent count, more than 200 ncAAs have been incorporated into both
eukaryotic and prokaryotic organisms in vivo through the suppression of nonsense or
frameshift codons [92] (Figure 2.20). These feature a diverse suite of functionalized
side-chains, including fluorescent and spectroscopic probes, mimics of post-
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translational modifications, photocaged amino acids, photocrosslinkers, metalchelating groups, and bioorthogonal handles [92,93]. It should be noted that nearly all
the ncAAs incorporated through the in vivo suppression of nonsense or frameshift
codons feature substitutions on the alpha carbon; the incorporation of amino acids
with modified backbones, such as β-amino acids, D-amino acids, N-methylated amino
acids, presents additional complications [94]. In many cases, the desired ncAA is not
commercially available, and will thus need to be synthesized.

Figure 2.20: A representative selection of genetically incorporated ncAAs. Adapted from Xiao
and Schultz (2016).

2.4.1.2.2 Reassigned codons

The reassigned codon is usually the amber stop codon (TAG), as this is the least
common stop codon in E. coli, with only 321 instances in one common strain [95].
(Reassignment of the amber codon for ncAA expression is often referred to as “amber
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suppression.”) The opal (TGA) and ochre (TAA) stop codons have also been
reassigned, as have quadruplet frameshift codons such as AGGA [96][97].
2.4.1.2.3 Orthogonal aminoacyl-tRNA synthetase/tRNA (o-aaRS/tRNA) pairs

An orthogonal aminoacyl-tRNA synthetase/tRNA pair is one that does not cross-react
with any of the endogenous aaRS/tRNA pairs or canonical amino acids. In other
words, the orthogonal synthetase (o-RS) specifically aminoacylates its cognate
orthogonal tRNA (o-tRNA) with its designated ncAA. It does not aminoacylate any
of the endogenous tRNAs, nor does it aminoacylate its cognate o-tRNA with any of
the canonical amino acids. Furthermore, the o-tRNA is not recognized by any of the
endogenous synthetases. While co-translation of more than one ncAA has been
reported, it requires that all the o-aaRS/tRNA pairs be mutually orthogonal, in
addition to being orthogonal to the endogenous translation machinery [97][98].
Orthogonality is thus a function of context, and varies according to host organism.
The orthogonal aaRS/tRNA pair is typically imported from a source organism that
belongs to a domain of life distinct from that of the host. For instance, the
aaRS/tRNA pairs most commonly used in E. coli derive from methanogenic
archaebacteria, while the pairs most commonly used for expression in eukaryotic
systems are borrowed from E. coli. Researchers have made progress in the generation
of mutually orthogonal aaRS/tRNA pairs through rational design and directed
evolution methods [98,99]. Nevertheless, this is an active field of research, and
remains a bottleneck for the co-translational incorporation of arbitrarily many ncAAs.
The aaRS/tRNA pairs most commonly used for the genetic incorporation of
noncanonical amino acids in E. coli are the tyrosyl aaRS/tRNA pair from the
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methanogenic archeon Methanocaldococcus jannaschii (MjTyrRS/tRNA), and the
pyrrolysl aaRS/tRNA pairs from Methanosarcina barkeri and Methanosarcina mazei,
methanogenic archaea that genetically encode the rare amino acid pyrrolysine
(MbPylRS/tRNA and MmPylRS/tRNA) (Figure 2.21).
MjTyrRS/tRNA is generally used for the incorporation of para-substituted
tyrosine analogs. In this project, we have used it for the incorporation of
azidophenylalanine (FAz, a substrate for SPAAC) and tetrazinephenylalanine (FTet, a
substrate for iEDDA) into the coat protein of the P22 bacteriophage. Incidentally,
TyrRS/tRNACUA was the first orthogonal aaRS/tRNA pair to be used for in vivo code
expansion when, in 2001, the Schultz group reported the genetic incorporation of pmethoxyphenylalanine into dihydrofolate reductase in E. coli [100].

Figure 2.21: Orthogonal aminoacyl-tRNA synthetases used for amber suppression in E. coli.
(A) Crystal structure of a Methanocaldococcus jannaschii tyrosyl-tRNA synthetase dimer specific
for O-methyl-tyrosine. MjTyrRS is generally used for the incorporation of para-substituted tyrosine
analogs. From PDB 1U7X. (B) Crystal structure of the Methanosarcina mazei pyrrolysyl-tRNA
synthetase in complex with adenylated propionyl lysine. MmPylRS is generally used for the
incorporation of lysine nalogs. Images generated from Protein Data Bank (PDB) 1U7X (A) and
4CH5 (B).
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In their natural context, the MbPylRS/tRNA and MmPylRS/tRNA pairs are
responsible for the ribosomal incorporation of pyrrolysine—one of the rare amino
acids mentioned at the beginning of this section—into methylamine
methyltransferases in methanogenic archaea [101]. In the context of genetic code
expansion, MbPylRS/tRNA and MmPylRS/tRNA are adaptable to a wide range of
ncAA substrates: they are generally used to incorporate lysine analogs, but can be
coaxed into accepting ncAAs with very different side-chains, such as L-phenylalanine
[Wang, Russell, Wang, Wan, et al., 2011]. In this project, we have used
MbPylRS/tRNACUA for the incorporation of norbornyllysine (KNorb, a substrate for
iEDDA).
Once a noncanonical amino acid and an orthogonal aaRS/tRNA pair have been
selected, the synthetase is engineered to specifically recognize the chosen ncAA. This
is accomplished through a series of positive and negative selections, as first
demonstrated by the Schultz group [100]. In the positive selection, the synthetase
library is co-transformed with an essential gene (such as an antibiotic resistance
marker) in which an amber codon has been introduced at a permissive site. The
library is grown in medium supplemented with the ncAA, and the relevant antibiotic
is added after induction of the resistance factor. Synthetase mutants that aminoacylate
the orthogonal tRNACUA with the ncAA produce functional copies of the resistance
marker, leading to cell survival. Synthetase mutants that do not aminoacylate the
orthogonal tRNACUA generate only non-functional truncated versions of the resistance
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factor, leading to cell death and elimination from the library. In the negative selection,
the library of active site synthetase mutants that survived the positive selection is coexpressed with a toxic gene product (such as the ribonuclease barnase) in which
amber codons (TAG) have been introduced at permissive sites. Promiscuous
misacylation of the orthogonal tRNACUA with canonical amino acids results in
ribosomal read-through of the barnase gene. As a result, the cell dies, and the mutant
is eliminated from the library. This process may be repeated for several rounds until

Figure 2.22: Double-sieve selection of active site aminoacyl-tRNA synthetase mutants specific for
a given noncanonical amino acid. See text for details. From Lang and Chin (2014).

an acceptable library is generated (Figure 2.22) [54,100].
2.4.2 Putting It All Together
Site-specific incorporation of the ncAA in E. coli is fairly straightforward once the
orthogonal machinery is in hand. First, the repurposed codon is introduced at a
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permissive site in the target protein through standard mutagenesis protocols. Then, the
orthogonal aaRS/tRNA pair and the target protein are introduced into the expression host
by co-transformation. (The aaRS/tRNA is typically housed on a “machinery plasmid,”
while the protein of interest is housed on a protein expression plasmid (Figure 2.23).
Care must be taken to ensure that these plasmids are mutually compatible). The dedicated
ncAA is usually provided in the growth medium, but can also be supplied by an
engineered biosynthetic pathway in the host organism [102]. Efficiency of ncAA
incorporation (i.e., the ratio of full-length to truncated protein) varies between 10% and
100%, depending on codon context, host strain, and the efficiency of the synthetase [103].
The decrease in efficiency can be attributed to the fact that the amber suppressor tRNA
competes with release factor 1 (RF1) for the A site of the ribosome.

Figure 2.23: Plasmids used in amber suppression. Co-transformation of the
machinery plasmid, which carries the o-tRNA and the o-aaRS, with the protein
expression plasmid, which carries the protein of interest. From Cooley (2018).

2.4.3 Noncanonical Amino Acids and Genetic Code Expansion
Engineering a bacterial system with multiple reassigned codons encoding multiple ncAAs
represents one of the current frontiers of code expansion research. Much of the recent
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work has focused on the generation of free codons, and has tended to fall into two
categories: genome-wide codon compression schemes and codon creation schemes.
Genome-wide codon compression schemes take advantage of the degeneracy of the
standard genetic code, which uses 64 distinct codons to encode only 21 “letters” (the 20
canonical amino acids plus STOP). Apart from tryptophan and methionine, all the
canonical amino acids use more than one codon; leucine and arginine use six each
(Figure 2.18, above). Thus, it should be possible to generate blank codons by
consolidating synonymous codons. A naïve analysis would suggest it is possible to
liberate 43 codons for reassignment by consolidating all redundant codons and deleting or
repurposing the corresponding tRNAs. However, the naïve analysis disregards the role of
wobble pairs and post-transcriptional anticodon modifications, as well as redundancies in
the tRNA population. A meticulous examination by Lajoie et al. determined that a
theoretical maximum of 27 new codons are accessible by codon compression in E. coli,
for a total of 27 novel + 20 canonical = 47 amino acids [104].
The first demonstration of genome-wide codon compression came in 2013, when the
Church group reported the reassignment of all 321 amber nonsense codons (TAG) in E.
coli MG1655 to the synonymous ochre nonsense codon (TAA). Elimination of TAG
made it possible to delete RF1, since RF2, the other release factor in E. coli, recognizes
both ochre (TAA) and opal (TGA) codons and is thus sufficient for termination in ΔRF1
strains. (RF1 recognizes TAG and TAA. Deletion of RF1 produced a strain in which
amber suppression does not compete with a release factor for the ribosomal A site [95].
More recently, the Church group has reported progress toward the genome-wide
reassignment of 7 codons in E. coli [105]. Similarly, the Chin group has developed a
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recombinogenic system for the iterative stepwise replacement of long (~100kb) segments
of the E. coli, which allows for the systematic evaluation of distinct synonymous
recoding schemes [106].
The second approach, codon creation, is more radical in nature. It begins with the
observation that the standard genetic code uses triplet codons of four nucleotides,
yielding a total of 43 = 64 distinct codons. However, there is no obvious a priori reason
why biology settled on these numbers; perhaps they are fungible. An organism that used
three nucleotide pairs—six nucleotides—would in theory have access to 63 = 216 distinct
triplet codons. Similarly, an organism that employed quadruplet codons would have 44 =
256 distinct codons at its disposal.
The idea of using an expanded set of nucleotides was first suggested in 1962, and
studied experimentally in vitro from the 1980s onward [107–109]. But it was not until
2014 that the Romesberg group demonstrated the stable propagation of an expanded sixnucleotide system over multiple generations in a live organism (E. coli) [110]. A variant
of this six-nucleotide system was subsequently used to link the propagation and
transcription of nonstandard nucleotides to the translation of two noncanonical amino
acids: a noncanonical lysine analog (via the MbPylRS/tRNA pair) and a noncanonical
phenylalanine analog (via the MjTyrRS/tRNA pair) [111,112].
Other researchers have developed orthogonal translation systems to adapt the
ribosome to a quadruplet code. Normally, because of its pivotal role in cellular processes,
the ribosome cannot be mutated or otherwise engineered without catastrophic (and often
lethal) results. However, by mutating the ribosomal binding site (the Shine-Dalgarno
sequence) on the 5’end of mRNAs and the complementary anti-Shine-Dalgarno sequence
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on the 3’-end of the E. coli 16S rRNA, the Chin group effectively created a “virtual”
translation system in which orthogonal ribosomes specifically translate orthogonal
mRNAs and orthogonal mRNAs are specifically translated by orthogonal ribosomes. The
resulting orthogonal translation system essentially functions as a virtual operating system,
allowing the orthogonal ribosome to be adapted to quadruplet codons without harming
the host [98,113–115].
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Chapter 3: ROMP-Based Strategy
Published in Int J Environ Res Public Health, 2015 Oct 9;12(10):12543-55

3.1 Chapter Introduction
For much of the twentieth century, “drug discovery and development” was synonymous
with the identification and synthesis of biologically active small molecules derived from
natural products or created through rational-design processes. However, since 1980 the
number of new chemical entities (NCEs) registered each year with the FDA has remained
more or less constant, despite the proliferation of newly identified drug targets and the
considerable financial and scientific resources devoted to drug discovery [3,116].
Bioactive peptides, which are very potent, highly selective, and do not produce toxic
metabolites upon degradation, are a promising alternative to small molecules for drug
discovery and development [116,117].
There are numerous natural reservoirs of bioactive peptides, such as the venom
arsenal of predatory marine snails, spiders, and other organisms, that have yet to be
thoroughly explored and characterized [118–122]. Ziconotide (Prialt®), a peptide drug
first identified in the venom of the marine snail Conus magus, is the first non-opioid
analgesic and is currently used to alleviate chronic pain in HIV and cancer patients
[6,122,123].
The primary obstacle to the widespread use of bioactive peptides has been their
unfavorable pharmacokinetic profile. Unstructured peptides are degraded by endogenous
proteases and are thus relatively unstable in vivo [9]. Additionally, most peptides, with
the exception of specialized cell-penetrating peptides, cannot cross the blood-brain
barrier (BBB) [18]. However, peptide therapeutics derived from venomous organisms
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exhibit improved pharmacokinetic profiles, in part due to the structural integrity provided
by disulfide bonds. Ziconotide, for example, is stabilized by three disulfide bonds that
confer increased resistance to endogenous proteases. The structural stability of ziconotide
ensures prolonged relief when it is administered as a pain therapy [4–6]. However,
ziconotide does not cross the BBB, and must be administered by intrathecal injection [4].
An alternative to intrathecal injection for the administration of ziconotide, in which the
peptide was encapsulated in a viral nanocontainer and delivered across the BBB via a
trojan horse strategy, was recently described [18].
Packaging peptides in a nanocontainer delivery system is an effective strategy for
improving their pharmacokinetic profile, as the nanocontainer can protect the peptide
during transport and release at the site of its molecular target. The list of macromolecules
that have been investigated for their potential as delivery vectors includes polymeric
nanoparticles [11], micelles [124], liposomes [10], DNA origami structures [14], and
protein cages such as viral capsids (with the infectious genome removed) and ferritins
[15,16]. Regardless of the type of macromolecule used, nanocontainer delivery systems
generally consist of three steps: packaging of the pharmacological agent, targeting of the
loaded nanocontainer to the appropriate site in vivo, and disassembly or release of the
active compound. While strategies for packaging and targeting nanocontainers have been
extensively studied, controlled release of the encapsulated drug remains problematic
[18,125,126].
In large part, hurdles to nanocontainer disassembly persist because the release
mechanism needs to function under physiological conditions of moderate temperature,
neutral pH, and aqueous environment.
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Here, we present a strategy for inducing disassembly of a nanocontainer derived from
the viral capsid of the Salmonella typhimurium bacteriophage P22 under physiological
conditions. The P22 capsid is a T = 7 icosahedral lattice composed of 420 copies of P22
coat protein (CP) that self-assemble in the presence of approximately 300 copies of the
P22 scaffold protein (SP) [127]. A truncated version of the SP, consisting of the last 66
C-terminal residues, is sufficient for self-assembly of the procapsid [19]. The Douglas
group recently developed a system for packaging arbitrary gene products into the P22
capsid shell by using standard recombinant methods to create a fusion protein consisting
of an arbitrary cargo protein joined to the P22-SP C-terminus by a thrombin cleavage site
[17]. Various gene products have been loaded into the P22 capsid in this manner,
including the fluorescent proteins EGFP and mCherry, the enzyme alcohol
dehydrogenase D, and ziconotide [17,18,20].

Figure 3.1. A dissociative viral nanocontainer for peptide drug delivery. A viral nanocontainer is
conjugated to strained olefins that undergo a ring opening polymerization reaction (ROMP) in the
presence of Grubbs II Catalyst. The ROMP reaction disrupts the architecture of the nanocontainer,
resulting in disassembly and release of the encapsulated peptide cargo.
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Our strategy for triggered disassembly of the P22 nanocontainer employs Ring
Opening Metathesis Polymerization (ROMP), an olefin metathesis reaction that is known
to proceed under physiological conditions in the presence of a ruthenium catalyst (Grubbs
Catalyst) [128,129]. The ROMP disassembly strategy is desirable as it can be triggered to
release the cargo in response to a defined stimulus, which will provide temporal control
over the pharmacokinetics of the encapsulated drug [130]. Specifically, we conjugated
the ROMP substrate norbornene (5-Norbornene-2-carboxylic acid) to the exterior of
loaded P22 nanocontainers and used ruthenium catalysts to trigger the ROMP reaction.
Our results indicate that the ROMP reaction disrupts the P22 nanocontainer architecture
in such a way as to produce limited release of a GFP reporter under physiological
conditions (Figure 3.1).

3.2 Materials and Methods
3.2.1. Construction of P22GFP Nanocontainers
P22GFP nanocontainers were constructed as described in O’Neil et al. [17] (Figure
3.2A). Briefly, BL21 E. coli were transformed with a plasmid containing the genes for
the P22 coat protein and an engineered GFP-scaffold protein fusion. Transformed E. coli
were grown to OD600 = 0.6 and induced with isopropyl β-D-1-thiogalactopyranoside
(IPTG). Cells were harvested and lysed, and clarified lysates were subject to
ultracentrifugation over a 35% sucrose cushion. Viral pellets were further purified over a
sephacryl (S-500) size-exclusion column (GE Healthcare). Detection of GFP protein was
achieved by electrospray ionization mass spectrometry (45,515 Da for EGFP-SP141
fusions) to confirm successful encapsulation inside P22 nanocontainers.
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Figure 3.2. Construction of the P22GFP Nanocontainer. (A) Incorporation of cargo protein into P22 capsid.
When the P22 coat protein (green circles) is co-expressed with an engineered scaffold protein-cargo protein
construct (orange squares and purple circles, respectively), the nanocontainer self-assembles with the coat
protein on the exterior and the scaffold and fusion proteins on the interior. Here, the cargo protein is GFP. (B)
Dynamic Light Scattering (DLS) of unconjugated P22GFP nanocontainers reveals spherical entities with a mean
diameter of 49.8 nm. (C) TEM (Transmission Electron Microscopy) image of P22 nanocontainers. The
assembled capsids are homogeneous in size, shape, and packaging. Scale bar = 100 nm. (D) Confocal
fluorescence microscope image of P22GFP at 100× magnification confirms the presence of GFP.

3.2.2. Confocal Fluorescence Microscopy Characterization of P22GFP Nanocontainers
Spinning disc confocal microscopy was carried out on a Perkin Elmer UltraView ERS
instrument using a GFP filter. Samples of P22GFP were diluted 16x with nanopure water,
mounted onto a slide, and examined at 100× magnification. Images were produced with
Volocity 3D Image analysis software.

3.2.3. Conjugation of Norbornene to P22GFP Nanocontainers
To conjugate norbornene to surface-exposed lysine residues on the P22 bacteriophage
capsid, 1.4 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 1.6 mg Nhydroxysuccinimide (sulfo-NHS) were added to 1 mL of a (1 mg/mL) solution of 5-
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norbornene-2-carboxylic acid in 0.1M phosphate buffer (pH 6.0) (all reagents were
purchased from Sigma-Aldrich). The solution was allowed to react at room temperature
with intermittent vortexing. After 30 minutes, 0.1 M dibasic phosphate stock was added
dropwise to raise the pH to 7.5. To this activated 5-Norbornene-2-carboxylic acid solution
was added 250 µL of (13.2 mg/mL) P22GFP in PBS. After reacting at room temperature
overnight on a shaker at 250 rpm, the product was concentrated by means of a 10 KDa
MWCO centrifugal filter device (Amplicon) and resuspended in pH 7.0 phosphate buffer.

3.2.4. Construction of P22His6GFP Nanocontainers
A Q5 site-directed mutagenesis kit was used to insert a hexahistidine tag at the Nterminal of the SP141 gene of the P22-GFP expression plasmid via standard PCR
protocols. Transformed clones were screened for correct insertion of the hexahistidine tag
and confirmed by Sanger sequencing (Genewiz). P22His6GFP Nanocontainers were
expressed and purified as described above in section 2.1.

3.2.5 Conjugation of Norbornene to P22His6GFP Nanocontainers
5-Norbornene-2-carboxylic acid was conjugated to P22-His6GFP Nanocontainers as
described above in section 3.2.3.

3.2.6. MS Characterization of P22GFP_Norb Nanocontainers
Mass Spectrometry (MS) analyses were carried out on a 6520 Accurate Mass QTOF
LC/MS system (Agilent Technologies). P22 nanocontainers conjugated with 5Norbornene-2-carboxylic acid (1 µL, 1.0 mg/mL) were injected into an Agilent Eclipse
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Plus C18 column and eluted with 99.9% ACN, 0.1% formic acid. Spectra were produced
using Agilent MassHunter Qualitative Analysis software.

3.2.7. Ring Opening Metathesis Polymerization (ROMP) of P22GFP_Norb
Nanocontainers with Grubbs II catalyst
Two samples of (2 mg/mL) P22-GFP-Norbornene were transferred to microfuge tubes in
aliquots of 20 µL. To the first (control) sample was added 1.7 µL of nanopure H2O. To
the second (experimental) sample was added 1.7 µL of 0.01% (w/v) (10 mol%) Grubbs II
Catalyst (Sigma-Aldrich). Samples were vortexed and allowed to react 24 hours at room
temperature.

3.2.8. Transmission Electron Microscopy (TEM) Characterization of P22-GFP
Nanocontainers and Post-ROMP P22GFP_Norb Nanocontainers
TEM images were produced on a JEOL JEM 2100 instrument with an acceleration
voltage of 200 kV and an FEI Tecnai G2 Spirit Twin instrument with an acceleration
voltage of 120kV. Samples were applied to a carbon-coated copper grid at a
concentration of 0.01 mg/mL, rinsed 3x with nanopure water, and stained 3x with 1%
(w/v) uranyl acetate solution, as described in Rames et al. (2014) [131]. Images were
processed and analyzed using ImageJ software.

3.2.9. DLS Characterization of P22GFP Nanocontainers
For Grubbs II-treated samples, dynamic light scattering (DLS) measurements were
recorded using a PD2000DLS instrument (PDDLS/Cool Batch 90T, Precision Detectors).
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Nanocontainers at a concentration of 1 mg/mL in pH 7.2 PBS were filtered through a 0.2
µm syringe filter and transferred to a 0.5 × 0.5 mm glass cuvette for DLS analysis. For
samples treated with AquaMet catalyst, DLS measurements were taken with an Antor
Paar Litesizer 500 instrument. Treated samples were loaded directly into a low-volume
quartz cuvette at a concentration of 10 µM for DLS analysis.

3.2.10. P22GFP Heat-Activated Disassembly Monitored by Native Agarose Gels
P22GFP_Norb samples were divided into eight aliquots of 15 µL each and heated for 10
minutes under a thermal gradient. Specifically, the first aliquot was heated at 50 °C, with
5 degrees added for each subsequent aliquot, so that the final aliquot was heated at 85 °C.
Samples were allowed to cool, mixed with loading buffer (40% glycerol, bromophenol
blue) and loaded into the wells of a 1.0% native agarose gel with unheated P22GFP and
P22GFP_Norb controls. Gels were run at 65 V for 2.5 hours in TAE buffer (40 mM tris,
20 mM acetic acid, 1 mM EDTA), then stained with coomassie blue and destained with
acetic acid and methanol. Images were produced using a Foto/Analyst FX imaging
system (Fotodyne).

3.2.11. Cargo-release Disassembly Assay
250 µL aliquots of a 2.5mg/mL solution of P22His6GFP_Norb in PBS were placed in
each of two microcentrifuge tubes. To the experimental sample was added 66.4 µL of a
3.2 mg/mL solution of AquaMet catalyst in ddH2O (final concentration 212 µg/mL). To
the control sample was added 66.4 µL of ddH2O. Samples were incubated at room
temperature overnight, then supplemented with 250 µL wash buffer (Tris-HCl (10 mM),
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imidazole (20 mM), NaCl (200 mM), pH 8) and 50 µL Ni2+ Sepharose beads and placed
on a nutator. After 1h, the beads were collected by centrifugation (1000g, 1m) and the
flowthrough removed. Beads were resuspended four times in 100 µL of wash buffer, then
eluted four times with 100 µL wash buffer supplemented with 200 mM imidazole. Wash
and elution fractions were monitored for absorbance at 280 nm and 495 nm (peak
absorbance of GFP) on a NanoDrop 2000c spectrophotometer (Thermo Scientific).

3.2.12. MTT cytotoxicity assay: VLP constructs
The cytotoxicity of VLPs was examined in BJ normal human foreskin epithelial
fibroblasts by MTT assay. 5000 cells were seeded in each well of a 96-well plate and
incubated with P22His6GFP and P22His6GFP_Norb in quadruplicate at three
concentrations: 1 µg/ml, 10 µg/ml, and 100 µg/ml. After 24h incubation, 20 µl of MTT
solution (5.0 mg/ml methyl tetrazolium salt in PBS) was added to each well and plates
were incubated for an additional 3h at 37°C in 5% CO2. After 3h, medium supplemented
with MTT solution was aspirated and 100 µl of acidified isopropanol was added to each
well. Spectrophotometric assays were conducted in a PowerWave HT Microplate
Spectrophotometer at 550 nm and 620 nm. The mean and standard deviation of the δOD
values were calculated by subtracting the 620 nm values from the 550 nm values. The
absorbance of control cells (untreated) was used as the 100% viability baseline.

3.2.13. MTT Cytotoxicity Assay: Catalyst
The cytotoxicity of AquaMet catalyst was examined in HELA and 1MEA cells by MTT
assay, as described above.
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3.3 Results
3.3.1. Characterization of P22-GFP Nanocontainers
The integrity of P22-GFP nanocontainers was determined using dynamic light scattering
(DLS), TEM, and spinning disk confocal fluorescence microscopy. DLS analysis
detected spherical nanocontainers with a mean diameter of 49.8 nm (expected mean
diameter 50.0 nm) [132]. TEM images revealed capsids that are homogeneous in size and
shape (Figure 2B and 2C). Spinning disk confocal fluorescence microscopy at 100×
magnification and 16× dilution revealed a field of bright green dots, indicating the
successful encapsulation of GFP. DLS, TEM, and confocal fluorescence microscopy
characterization, together with prior MS data [17] confirmed the construction of P22-GFP
nanocontainers.

3.3.2. Characterization of Norbornene-Conjugated P22-GFP Nanocontainers
(P22GFP_Norb)
The P22GFP-norbornene conjugation reaction was monitored by MS analysis.
Compounds with masses corresponding to that of the P22 coat protein (expected mass
46,596 Da, observed mass 47,192 Da) plus an integral number (between 2 and 6) of
120 Da adducts was detected (Table 3.1). The 120 Da mass corresponds to a 5norbornene-2-carboxylic acid moiety conjugated to a free amine to form an amide bond
(Figure 3). A weighted average of the number of norbornene adducts per coat protein
monomer (with the weight determined by the relative abundance by volume of each
compound cited in Table 3.1) suggests there are slightly more than four norbornene
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moieties per coat protein monomer, or approximately (4 norbornene adducts per
monomer) × (420 coat protein monomers per nanocontainer) equates to 1700 norbornenes
per nanocontainer. Although the P22 coat protein contains 19 lysine residues that could
potentially couple with an activated 5-Norbornene-2-carboxylic ester, not all of these are
surface-exposed, which would explain why not all 19 lysines are conjugated with
norbornene.

Compound

Mass

Vol %

5
4
3
2
6
1
7

47,792.3
47,672.4
47,552.4
47,672.0
47,911.8
47,432.2
47,911.5

26.8
24.17
20.9
12.43
5.81
5.24
3.95

No. of
Norbornenes
5
4
3
4
6
2
6

Table 3.1. Compounds detected through MS analysis of norbornene-conjugated P22GFP nanocontainers. Seven P22-Norbornene compounds were detected by MS
analyses. The unconjugated coat protein had a baseline observed mass of 47,192 Da
(expected mass = 46,596 Da). Each additional conjugated norbornene adds an average
of 120 Da. to the baseline mass. The volume-weighted average is 4.12 norbornenes
per coat protein monomer.
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Figure 3.3. Conjugation of norbornene-COOH to the procapsid surface. (A) Norbornene-COOH is
activated with EDC and sulfo-NHS, leading to the formation of an amide bond with the ε-NH2 of
surface-exposed lysine residues. (B) Mass spectrum of unmodified capsid coat protein (m/z = 47,192).
(C) Mass spectrum of coat protein subunit conjugated with five norbornene subunits (m/z = 47,792).

3.3.3. TEM Characterization of P22GFP_Norb ROMP Reaction
The integrity of the P22 nanocontainers before and after conjugation with norbornene and
treatment with Grubbs II catalyst was monitored by TEM. TEM revealed that
P22GFP_Norb capsids treated with 10 mol% Grubbs II catalyst exhibited strained and
distorted morphologies when compared with untreated P22GFP_Norb (Figure 3.4).
Treated capsids also exhibited robust bridge structures at inter-capsid interfaces. The
ROMP reaction was functional under experimental conditions.
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Figure 3.4. Disassembly of P22 nanocontainer using Grubbs Catalyst-activated ROMP. (A) Reaction scheme of
ROMP (Ring Opening Metathesis Polymerization) reaction. P22 nanocontainers conjugated with norbornene are
treated at room temperature under physiological conditions with Grubbs II Catalyst, which triggers polymerization of
norbornene and disruption of nanocontainer conformation. TEM of nanocontainers before ROMP reaction (B), and
after ROMP (C), illustrate the morphological change. P22GFP_Norb nanocontainers treated with 10 mol% Grubbs II
catalyst exhibit strained and distorted morphologies when compared with untreated P22GFP_Norb nanocontainers.
Treated nanocontainers also exhibit robust bridge structures, suggesting that the ROMP reaction is occurring at both
intra- and inter-nanocontainer interfaces. Scale bar = 50 nm.

3.3.4. Characterization of Heat-Induced Dissociation of P22 Nanocontainer
P22 nanocontainers are known to undergo morphogenesis when heated. The
nanocontainers expand to a diameter of 64 nm when heated at 65 °C and shed the coat
protein pentons at each of the 12 fivefold axes of symmetry when heated at 75 °C. Heating
above these temperatures causes disassembly [17,47]. Native agarose gel characterization
illustrated that P22GFP_Norb nanocontainers begin to dissociate after 10 minutes in the
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60–70 °C range, as indicated by the disappearance of the 30 MDa band (Figure 3.5). The
streaking towards the top of the gel in lanes 6-10, corresponding to temperatures of 65 °C
and above, is likely due to the formation of large amorphous aggregates, which are
visible in the background of TEM images of samples of P22-GFP-Norbornene heated for
10 minutes at 65 °C (Figure 3.5A). Significantly, TEM images of P22-GFP-Norbornene
treated with 10 mol% Grubbs II catalyst and TEM images of P22-GFP-Norbornene
heated for 10 minutes at 65 °C show similar patterns of morphological distortion,
suggesting dissociation of the nanocontainers (Figure 3.5).

Figure 3.5. Heat-induced disassembly of wild-type P22
nanocontainers vs. ROMP-triggered morphological distortion
of P22GFP_Norb nanocontainers. (A) Heating of P22GFP
nanocontainers at 65 °C for 10 m results in a rough, distorted
texture that indicates the beginning of capsid dissolution. P22GFP-Norb nanocontainers treated with 10 mol% Grubbs II
catalyst exhibit a similar pattern of distortion. (B) Native 1%
agarose gel of heated P22GFP_Norb nanocontainers shows the
onset of disassembly after 10 m at 65 °C. All TEM images at 20k
magnification.
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3.3.5. A Water-soluble Ruthenium Catalyst
While the Grubbs II catalyst is known to be
water-tolerant, its solubility in aqueous media is
extremely limited. We thus reasoned that a
water-soluble version of the catalyst would
yield improved results. Although no watersoluble version of the Grubbs catalyst was
commercially available when we began this
project, that situation subsequently changed: a

Figure 3.6: AquaMet catalyst

commercial version of the Hoveyda-Grubbs ruthenium complex featuring a quaternary
ammonium group appended to the N-heterocyclic carbene ligand for improved water
solubility ("AquaMet") is now available (Figure 3.6).
To test the performance of the AquaMet catalyst with norbornene-conjugated
nanocontainers, a series of reactions with increasing catalyst concentrations was
implemented, as outlined in Figure 3.7. To monitor for non-specific catalyst effects, we
used as controls P22 nanocontainers that had not been conjugated with norbornene.
Reactions were incubated overnight at room temperature and characterized by native
agarose electrophoresis, DLS, and TEM.

3.3.6 Native Agarose Characterization of Water-soluble Catalyst Reaction
Characterization by native agarose electrophoresis indicates a clear difference in the
behavior of nanocontainers conjugated with the ROMP-substrate norbornene
(P22His6GFP_Norb) and nanocontainers that lack the norbornene moiety (P22His6GFP)
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(Figure 3.7). Although a non-specific catalyst effect is observed at high catalyst
concentrations (Lane 5), conjugated nanocontainers (P22His6GFP_Norb) appear to
dissociate at catalyst concentrations that have no observable effect on non-conjugated
nanocontainers (P22His6GFP_Norb). Note also that the smear observed in conjugated
nanocontainers treated with moderate to high catalyst concentrations (Lanes 7 - 10)
resembles that observed in heat-induced dissociation (Figure 3.5, above).

Figure 3.7: Native agarose of electrophoresis of unconjugated nanocontainers (P22His6GFP) and norbornene-conjugated P22
nanocontainers (P22His6GFP_Norb) indicates capsid disassembly at significantly lower catalyst concentrations for unconjugated
nanocontainers.
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3.3.7 DLS Characterization of Water-soluble Catalyst Reaction
DLS analysis of norbornene-conjugated nanocontainers (P22His6GFP_Norb) treated with
water-soluble ruthenium catalyst revealed a pronounced, dose-dependent increase in both
the mean hydrodynamic diameter and the polydispersity index with increasing catalyst
concentration (Figure 3.8). These results are consistent with ROMP-induced dissociation
and/or aggregation.
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Figure 3.8: DLS
characterization of
norbornene-conjugated
nanocontainers. Images
show norborneneconjugated nanocontainers
(P22His6GFP_Norb) treated
with increasing
conscentrations of AquaMet
catalyst. All reactions
contain 90 µg
P22His6GFP_Norb
nanocontainers in a total
reaction volume of 82.5 µL.
Top panel: 13 µg/mL
catalyst, dmean = 60.7 nm,
PDI = 7.5%. Middle panel:
130 µg/mL catalyst, dmean =
210.7 nm, PDI = 21.9%.
Middle panel: 325 µg/mL
catalyst, dmean = 3055 nm,
PDI = 26.9%.

3.3.8 TEM Characterization of Water-soluble Catalyst Reaction
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TEM micrographs of functionalized (norbornene-conjugated) nanocontainers
(P22His6GFP_Norb) treated with water-soluble ruthenium catalyst exhibit significant
distortion in capsid morphology compared with nonfunctionalized nanocontainers treated
with comparable catalyst concentrations (Figure 3.9). Aggregates of what appear to be
disrupted and fused capsids are plainly visible in the functionalized samples (Figure
3.9B), but we were unable to locate any of the regular icosahedral structures
characteristic of untreated samples (Figure 3.9A). The observation of disordered
aggregates is consistent with a polymerization reaction that occurs at both intra- and

Figure 3.9: Representative TEM images. Images show (A) nonfunctionalized constructs (P22His6GFP_WT)
and (B) functionalized constructs (P22His6GFP_WT) and after with AquaMet catalyst. (A) No catalyst, 4k
magnification. (B) 0.325 mg/mL catalyst, 4k magnification. (C) No catalyst, 15k magnification. (D) 0.325
mg/mL catalyst, 15k magnification.

inter-nanocontainer interfaces.
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3.3.9 Cargo-release Assay
To monitor for the release of the His6-GFP cargo from disrupted capsids, control (no
catalyst) and experimental (0.212 mg/mL AquaMet catalyst) samples of P22His6GFP_Norb
were incubated with Ni2+ Sepharose beads then washed and eluted, as described above. The
four wash fractions and four elution fractions were monitored for absorbance at 280 nm
(aromatic amino acids)
and 495 nm (GFP λmax).
A significant peak was
observed in the elution
fractions of the
experimental sample at
both wavelengths (Figure
3.10). No peak was
observed in the elution
fractions of the control
sample. These results
demonstrate induced
release of the cargo
protein at nearphysiological conditions

Figure 3.10: Cargo-release assay. Incubation of catalyst-treated and untreated
nanocontainers with Ni2+-sepharose beads indicates release of His6GFP reporter
in treated nanocontainers.

(PBS, 25°C).
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3.3.10 Cytotoxicity of VLP constructs
To monitor cytotoxicity of the P22His6GFP and P22His6GFP_Norb constructs, an MTT
assay was carried out using BJ normal foreskin epithelial cells. No evidence of
cytotoxicity was found for treatment with VLP constructs at concentrations up to 100
µg/mL. (Figure 3.11)
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Figure 3.11: Cytotoxicity of VLP constructs. MTT cytotoxicity assay in BJ normal human cells indicates
no significant cytotoxicity for either P22GFP_WT (nonfunctionalized control) or P22GFP_Norb
(functionalized) constructs.

3.3.11 Cytotoxicity of Catalyst
Cytotoxicity of the AquaMet catalyst was monitored by MTT assay in HELA and 1MEA
cells (Figure 3.12). While moderate cytotoxicity (>10% cytotoxicity, <60% viability)
was found for catalyst concentrations above 200 µg/mL in HeLa cells, this value is
significantly higher than the 100 µg/mL needed to disrupt functionalized
P22His6GFP_Norb constructs without affecting nonfunctionalized P22His6GFP
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constructs (Figure 3.7). In addition, no significant cytotoxicity was found for 1MEA
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Figure 3.12: Cytotoxicity of AquaMet ruthenium catalyst. MTT cytotoxicity assay indicates no significant
cytotoxicity in 1MEA (mus musculus cancer hepatocytes) and moderate cytotoxicity in HeLa (human
cancer) cells at catalyst concentrations significantly higher than those needed to achieve induced
disassembly (0.05 – 0.1 mg/ml) in functionalized P22GFP_Norb constructs.

3.4 Chapter Conclusions
Delivering peptide drugs to their site of action in a controlled manner remains a
significant challenge. Here we describe a drug delivery system that encapsulates a
peptide cargo within a viral nanocontainer and employs a catalyst-driven ROMP reaction
to trigger release of the encapsulated cargo. Specifically, activated 5-Norbornene-2carboxylic acid was conjugated to surface-exposed lysine residues on the P22
bacteriophage procapsid in a yield of approximately four norbornene moieties per P22
coat protein monomer. Treatment of the P22-GFP-Norbornene nanocontainer with
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Grubbs II catalyst precipitated a ROMP reaction that distorts the morphologies of
individual nanocontainers. These results illustrate a method for inducing conformational
changes in engineered P22 bacteriophage nanocontainers that will enable the controlled
release of loaded peptide cargos.
Recent studies have illustrated that viral capsid nanoplatforms, such as the P22 capsid
used in this study, are not toxic in cell lines, nor when administered to mice [18,133]. In
particular, the Kaiser et al. study provided a baseline for protein nanoplatform
degradation and clearance in vivo. The Kaiser study found that single injections of naïve
and immunized mice with representative protein cage nanoplatforms derived from the
Cowpea chlorotic mottle virus (CCMV) and the heat shock protein (Hsp) of the
hyperthermophilic archaeon Methanococcus jannaschii did not lead to overt toxicity.
Protein cages were broadly distributed throughout most tissues and organs, were rapidly
excreted within 24 hours, and did not exhibit long-term persistence in tissue or organs.
While a comprehensive analysis has yet to be performed on the P22 capsid, these results
suggest that the protein cage of P22 capsid may also be safe for biomedical applications.
In addition, preliminary reports indicate that the polynorbornene produced by the ROMP
disassembly reaction is not cytotoxic [134].
The Grubbs catalyzed ROMP strategy for nanocontainer disassembly that we have
pursued here is novel. Previous strategies for nanocontainer disassembly have required the
manipulation of environmental conditions such as pH and temperature that cannot be
readily controlled in vivo [9]. Our ROMP-based method builds upon the resurgence in
material and natural product chemistry applications that followed the introduction of
solvent-tolerable catalysts such as the ruthenium-based Grubbs catalyst in the 1990s and
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2000s. The Grubbs catalyst not only accelerated metathesis reactions to a physiologically
relevant timescale (in many cases a matter of minutes), but also allowed for the use of
water-based solvents and proved effective at initiating metathesis reactions in minimal
concentrations [66]. In addition, the water-compatible properties of the ROMP reaction
suggests that the catalyst could be administered to patients via intravenous drip therapy,
similar to saline.
While we have successfully demonstrated the ROMP reaction, there are several
questions that need to be addressed to make this a viable method in vivo. For example,
the Grubbs II catalyst applied is ruthenium-based, and ruthenium (Ru) is mildly toxic
[135,136]. However, the amount of Grubbs II catalyst needed to initiate a ROMP reaction
is relatively small. Here we applied 10 mol% Grubbs II catalyst, however, other studies
report effective catalysis in water with amounts as low as 2 mol% [137]. Additionally,
there have been efforts to produce ROMP catalysts based on elements with reduced
toxicity, such as molybdenum (Mo) and tungsten (W) [138,139]. Replacing Ru with Mo
or W would extend the potential application of in vivo ROMP nanocontainer dissociation.
Together with our findings, these recent studies pave the way for the development of a
ROMP-triggered P22-based nanocontainer system for the controlled delivery of peptide
therapeutics.
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Chapter 4: Click-based Strategy (iEDDA and SPAAC)
4.1 Chapter Introduction
As noted above in the general introduction, the “click-based” approach is an alternative
strategy for triggering capsid disassembly under physiological conditions. Central to this
approach is the finding that substitution and insertion mutations at the T183 site of the Adomain in the P22 coat protein results in capsids that are permissive of self-assembly but
thermally unstable relative to wild-type [22]. By clicking a functionalized, comparatively
large macromolecule onto a bioorthogonal handle installed at the sensitive T183 site, we
aim to mimic, in an inducible manner, a destabilizing T183 mutation.
The conjugation methods described above, in chapter 3, were non-specific, targeting
all surface-exposed lysine residues for norbornene functionalization. However, the
present strategy calls for the site-specific incorporation of a bioorthogonal handle at T183.
This will be accomplished through genetic code expansion. The genetic incorporation of
noncanonical amino acids (ncAAs) into the coat protein of P22 procapsids will allow us
to investigate the potential destabilizing effect of two bioorthogonal reactions: the
iEDDA reaction between an electron-poor diene and an electron-rich dieneophile, and the
SPAAC reaction between an azide and a strained cyclic alkyne. Three ncAAs will be
incorporated into the P22 procapsid: (1) azidophenylalanine (FAz), a SPAAC substrate;
and (2) tetrazinephenylalanine (FTet) and (3) norbornenelysine (KNorb), both iEDDA
substrates (Figure 4.1). All three of these ncAAs have been site-specifically introduced
to proteins by amber suppression [50,65,140]. (DBCO, the bioorthogonal partner to FAz,
is too bulky for ribosomal incorporation.)
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Figure 4.1: Noncanonical amino acids (ncAAs) used in this project. Azidophenylalanine (FAz) is a
substrate for SPAAC, while methyltetrazinephenylalanine (FTet) and norbornenelysine (KNorb) are substrates
for iEDDA.

To compete with endogenous cellular processes, an ideal bioorthogonal reaction
should have second-order rate constants of 104 M-1 s-1 or higher and produce quantitative
or near-quantitative yields [50]. The inverse electron-demand Diels-Alder cycloaddition
(iEDDA) reaction between tetrazines and strained trans-cyclooctenes (sTCOs), with
second-order rate constants approaching 105 M-1 s-1, comes close to the ideal. However,
sTCOs are expensive and relatively unstable, with a biological half-life less than 24h
[141]. For this proof-of-concept study, we have chosen to work instead with norbornene,
which is slower (1 M-1 s-1 - 10 M-1 s-1), but inexpensive and stable. Strain-promoted
azide-alkyne cycloaddition (SPAAC), while slower than iEDDA (k ~ 10-2 M-1 s-1 – 101
M-1 s-1), has a number of practical advantages. For one, the amber suppression system for
the ribosomal incorporation of FAz is particularly robust. In addition, azidophenylalanine
and its bioorthogonal partner, DBCO, are both commercially available.
The “trigger molecules” used to click onto the sensitive T183 site consist of
functionalized short peptides and polyethylene glycol (PEG) polymers. For preliminary
proof-of-principle studies, simple polyglycine peptides with a single lysine for solubility

70

and functionalization (GGKGG) are used. It should be possible to adapt this method to
cell-penetrating peptides for downstream applications.
To summarize, the implementation of the click-based strategy outlined here consists
of three preliminary steps: (1) synthesis of the noncanonical amino acids FTet and KNorb
(FAz is commercially available); (2) construction and characterization of three different
P22_183ncAA nanocontainers (P22_T183KNorb, P22_T183FTet, and P22_T183FAz); and
(3) construction and characterization of the iEDDA trigger molecules (Tet-GGKGG and
Norb-GGKGG). The SPAAC trigger, DBCO-PEG, is commercially available.
The final step, induction and characterization of iEDDA and SPAAC, will be
characterized by native agarose electrophoresis, transmission electron microscopy (TEM),
and dynamic light scattering (DLS).
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4.2 Materials and Methods
Synthesis of noncanonical amino acids. 4-azido-L-phenylalanine (FAz) was obtained from
Santa Cruz Biotechnology. Nε-5-norbornene-2-yloxycarbonyl-L-lysine (KNorb) and 4-(6methyl-s-tetrazin-3-yl)phenylalanine (FTet) are not available commercially and needed to
be synthesized.
4.2.1 Synthesis and characterization of Nε-5-norbornene-2-yloxycarbonyl-L-lysine
(KNorb). Nε-5-norbornene-2-yloxycarbonyl-L-lysine (KNorb) was synthesized in three
steps according to a published protocol from commercially available reagents (Figure
4.2). The product was characterized via proton NMR and electrospray ionization mass
spectrometry (ESI-MS).

Figure 4.2: Synthesis and characterization of Nε-5-norbornene-2-yloxycarbonyl-L-lysine (KNorb).
(a) Synthetic route for KNorb. (b) 1H-NMR for KNorb (300 MHz, CD3OD). (c) ESI-MS spectrum of KNorb.
Expected mass: 282.16 Da. Observed mass: 282.16 Da.
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4.2.2 Synthesis and characterization of 4-(6-methyl-s-tetrazin-3-yl)phenylalanine (FTet).
4-(6-methyl-s-tetrazin-3-yl)phenylalanine (FTet) was synthesized in two steps according
to a published protocol from commercially available reagents (Figure 4.3). The product
was characterized via proton NMR and electrospray ionization mass spectrometry (ESIMS).

Figure 4.3: Synthesis and characterization of 4-(6-methyl-s-tetrazin-3-yl)phenylalanine (FTet). (A)
Synthetic route for FTer from Popchok et al. (2018). (B) ESI-MS spectrum for FTet. Expected mass:
259.26 Da. Observed mass: 259.10 Da. (C) 1H-NMR for FTet (300MHz, CD3OD ).

4.2.3 Construction of P22_CP183Amber expression plasmids.
The site-specific incorporation of noncanonical amino acids (ncAAs) via amber
suppression requires three genetically encoded components: (1) an orthogonal synthetase
(o-aaRS) specific for the chosen ncAA; (2) a cognate orthogonal t-RNA (o-tRNA); and
the gene of interest with an amber codon (TAG) at the mutation site. Typically these
three components are housed on two compatible plasmids that are co-transformed into the
host. In general, compatibility is determined by the origin of replication. The p15A origin
of replication and the ColE1 origin of replication used in this project are mutually
compatible. Also, while it is common for the o-aaRS and the o-tRNA to be housed on a

73

single “machinery” plasmid, this is not strictly necessary.
Two synthetase/tRNA pairs will be used: the MbPylRS/tRNACUA pair from the
archeon Methanosarcina barkeri, which has been modified to incorporate
norbornenelysine (KNorb) at the amber codon, and the MjTyrRS/tRNACUA pair from the
archeon Methanocaldococcus jannaschii, which has been modified to incorporate either
tetrazinephenylalanine (FTet) or azidophenylalanine (FAz) at the amber codon. Both pairs
are orthogonal to the endogenous translation machinery in E. coli.

4.2.4 Construction of the pP22_T183Amber plasmid.
The P22 assembler plasmid, which houses an IPTG-inducible expression cassette
containing the P22 coat protein (CP) and a GFP-scaffold (GFP-SP141) fusion protein, an
ampicillin resistance gene, and a ColE1 origin of replication, was obtained from the
Trevor Douglas lab. The ACC codon corresponding to the threonine at residue 183 of the
coat protein was then replaced with an amber codon (TAG) through site-specific
mutagenesis of the P22 assembler plasmid using a Q5 mutagenesis kit (NEB).
Construction of the pP22_T183Amber mutant was confirmed by Sanger sequencing
(Genewiz).

4.2.5 Construction of the pP22MVIIASP141_T183Amber plasmid.
The P22 assembler plasmid is genetically programmable. To create P22_T183ncAA
nanocontainers charged with the conotoxin MVIIA, GFP gene was replaced with a
sequence encoding MVIIA using a synthetic MVIIA construct (IDT) and Gibson
Assembly. Construction of the pP22MVIIASP141_T183Amber mutant was confirmed by
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Sanger sequencing (Genewiz).

4.2.6 P22_T183FAz expression system.
For the expression of P22_T183FAz, the pDule2CNF plasmid was obtained from the
Ryan Mehl lab. pDule2CNF encodes on a p15A backbone (1) a mutant M. jannaschii
tyrosyl synthetase (TyrRS mutated to FazRS) engineered to be specific for FAz, and (2)
TyrT, a cognate o-tRNA. It also encodes a spectinomycin resistance gene. Because
pP22_T183Amber features a ColE1 origin of replication, it could be co-transformed with
pDule2CNF without further modification.

4.2.7 Construction of the P22_T183KNorb expression system.
Site-specific incorporation of KNorb by amber suppression was first reported by the Jason
Chin lab, from which we obtained pBKPylS, a p15A plasmid that houses the M. barkeri
pyrrolysyl synthetase (MbPylRS), and psfGFP150TAGPyl-His6, a ColE1 plasmid that
incorporates (1) an orthogonal tRNA (PylT) and (2) a superfolder GFP reporter with an
amber codon at residue 150 and a C-terminal hexahistidine tag (sfGFP). In E. coli, KNorb
is accepted by MbPylRS without additional modification. The P22_T183KNorb expression
system used in this project consists of (1) pBKPylS, and (2)
pP22GFPSP141CP183Amber_pylT, a ColE1 plasmid that incorporates PylT and the
P22_183Amber expression cassette. pP22GFPSP141CP183AmberPylT was constructed
from pP22_T183Amber and psfGFP150TAGPyl-His6 by PCR amplification and Gibson
Assembly. Construction was confirmed by Sanger sequencing.
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4.2.8 Construction of the P22_T183FTet expression system.
For the expression of P22_T183FTet, the pBKTetS plasmid was used in conjunction with
pP22GFPSP141CP183AmberTyrT. pBKTetS, encodes MjTetRS, a MjTyrRS mutant
engineered for specificity to FTet. It was constructed from the pBKPylS backbone using
Gibson Assembly and a synthetic MjTetRS insert (IDT), which was designed from
specifications in a published report [50]. pP22GFPSP141CP183AmberTyrT was
constructed from pP22GFPSP141CP183AmberPylT (the plasmid used for P22_T183KNorb
expression) and a TyrT insert (IDT) using Gibson Assembly. Construction was confirmed
by Sanger sequencing.

4.2.9 Expression and purification of a superfolder GFP (sfGFP150KNorb) reporter.
BL21(DE3) E. coli were co-transformed with pBKPylS and psfGFP150TAGPylT-His6.
Transformed cells were grown in LB medium supplemented with kanamycin (25 µg ml-1),
tetracycline (12 µg ml-1), and Nε-5-norbornene-2-yloxycarbonyl-L-lysine (1 mM) and
induced with 0.2% arabinose at OD600 = 0.6. Cells were grown overnight and then
harvested, lysed, and purified over a Ni-sepharose column.

4.2.10 Expression of P22_T183KNorb nanocontainers.
BL21(DE3) E. coli were co-transformed with pBKPylRS and
pP22GFPSP141CP183AmberPylT (for expression of P22GFP_T183KNorb) or
pP22MVIIASP141CP183AmberPylT (for expression of P22MVIIA_T183KNorb).
Transformed cells were grown in LB medium supplemented with tetracycline, kanamycin,
and 1mM KNorb to OD600 = 0.6 and induced with 0.2% arabinose. After 4 hours, cells
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were harvested and lysed, and clarified lysates were subject to ultracentrifugation over a
35% sucrose cushion followed by dialysis against PBS.

4.2.11 Expression of P22_T183FTet nanocontainers.
BL21(DE3) E. coli were co-transformed with pBKTetRS and
pP22GFPSP141CP183AmberTyrT (for expression of P22GFP_T183FTet) or
pP22MVIIASP141CP183AmberTyrT (for expression of P22MVIIA_T183FTet).
Transformed cells were grown in LB medium supplemented with tetracycline, kanamycin,
and 1mM FTet to OD600 = 0.6 and induced with 0.2% arabinose. After 4 hours, cells were
harvested and lysed, and clarified lysates were subject to ultracentrifugation over a 35%
sucrose cushion followed by dialysis against PBS.

4.2.12 Expression of P22_T183FAz nanocontainers.
BL21(DE3) E. coli were co-transformed with pDule2CNF and
pP22GFPSP141CP183AmberPylT (for expression of P22GFP_T183KNorb) or
pP22MVIIASP141CP183AmberPylT (for expression of P22MVIIA_T183KNorb).
Transformed cells were grown in autoinduction medium supplemented with ampicillin,
spectinomycin, and 1mM FAz. After 36 hours, cells were harvested and lysed, and
clarified lysates were subject to ultracentrifugation over a 35% sucrose cushion followed
by dialysis against PBS.
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4.2.13 MS characterization of P22_T183ncAA nanocontainers.
Mass Spectrometry (MS) analyses were carried out on a 6520 Accurate Mass QTOF
LC/MS system (Agilent Technologies). P22 nanocontainers (1 µL, 1.0 mg/mL) were
injected into an Agilent Eclipse Plus C18 column and eluted with 99.9% ACN, 0.1%
formic acid. Spectra were produced using Agilent MassHunter Qualitative Analysis
software.

4.2.14 Transmission Electron Microscopy (TEM) characterization of P22_T183ncAA
nanocontainers.
TEM images were produced on an FEI Tecnai G2 Spirit Twin instrument with an
acceleration voltage of 120kV. Samples were applied to a carbon-coated copper grid at a
concentration of 0.01 mg/mL, rinsed 3x with nanopure water, and stained 3x with 1%
(w/v) uranyl acetate solution, as described in Rames et al. (2014) [131]. Images were
processed and analyzed using ImageJ software.

4.2.15 Dynamic Light Scattering (DLS) characterization of P22_T183ncAA
nanocontainers.
DLS measurements were taken with an Antor Paar Litesizer 500 instrument. Samples
were loaded directly into a low-volume quartz cuvette at a concentration of 10 µM in
ddH2O for DLS analysis.
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4.2.16 Native agarose electrophoresis of P22_183ncAA nanocontainers.
P22_183ncAA samples were mixed with loading buffer (40% glycerol, bromophenol
blue) and loaded into the wells of a 1.0% native agarose gel. Gels were run at 65 V for 2.5
hours in TAE buffer (40 mM tris, 20 mM acetic acid, 1 mM EDTA), then stained with
coomassie blue and destained with acetic acid and methanol. Images were produced
using a Foto/Analyst FX imaging system (Fotodyne).

4.2.17 Construction of Trigger Peptides.
To mimic an insertion mutation at the sensitive T183 site, “trigger” peptides with
biorthogonal handles will be clicked on to a biorthogonal partner at the sensitive T183
site. For preliminary proof-of-principle studies, simple polyglycine peptides are used.
However, it should be possible to adapt this method to cell-penetrating peptides for
downstream applications.

4.2.18. MTT cytotoxicity assay: VLP constructs
The cytotoxicity of VLPs was examined in BJ normal human foreskin epithelial
fibroblasts by MTT assay. 5000 cells were seeded in each well of a 96-well plate and
incubated with P22MVIIA_183FTet, P22GFP_183KNorb, P22MVIIA_183KNorb or
P22GFP_WT (control) in quadruplicate at three concentrations: 1 µg/ml, 10 µg/ml, and
100 µg/ml. After 24h incubation, 20 µl of MTT solution (5.0 mg/ml methyl tetrazolium
salt in PBS) was added to each well and plates were incubated for an additional 3h at
37°C in 5% CO2. After 3h, medium supplemented with MTT solution was aspirated and
100 µl of acidified isopropanol was added to each well. Spectrophotometric assays were
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conducted in a PowerWave HT Microplate Spectrophotometer at 550 nm and 620 nm.
The mean and standard deviation of the δOD values were calculated by subtracting the
620 nm values from the 550 nm values. The absorbance of control cells (untreated) was
used as the 100% viability baseline.

4.2.17.1 Synthesis of a tetrazine-conjugated trigger peptide (Tet-GGKGG) for use with
P22T183KNorb constructs.

For P22_T183KNorb constructs, a tetrazine-conjugated peptide is used to react with the
norbornene moiety at the sensitive T183 site. Tet-GGKGG was constructed in two steps.
First, a scaffold peptide (GGKGG) was synthesized via solid-phase peptide synthesis
(SPSS). Next, a tetrazine analog with an N-hydroxysuccinimide (NHS)-activated
carboxylic acid was conjugated to free amines at the N-terminal and lysine side chains
using standard solution-phase bioconjugation protocols. The product was purified by

Figure 4.4: Synthesis of the Tet-GGKGG trigger peptide. ESI-MS confirms synthesis of the
Tet-GGKGG trigger peptide (Expected mass 1345.6 Da, Experimental mass 1345.6 Da). The
activated tetrazine handle (prior to comjugation) appears in the inset.

HPLC and synthesis of Tet-GGKGG was confirmed by ESI-MS (Figure 4.4).
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4.2.17.2 Synthesis of a norbornene-conjugated trigger peptide (Norb-GGKGG) for use with
P22T183FTet constructs.

For P22 T183FTet constructs, a norbornene-conjugated peptide is used to react with the
tetrazine moiety at the sensitive T183 site. Tet-GGKGG was constructed in three steps.
First, a scaffold peptide (GGKGG) was synthesized via solid-phase peptide synthesis
(SPSS). Second, a norbornene with a carboxylic acid was activated with NHS. Finally,
the NHS-activated norbornene was conjugated to free amines at the N-terminal and lysine
side chains using standard solution-phase bioconjugation protocols. . The product was
purified by HPLC and synthesis of Tet-GGKGG was confirmed by ESI-MS (Figure 4.5).

Figure 4.5: Synthesis of the Norb-GGKGG trigger peptide. ESI-MS confirms synthesis of the Norb-GGKGG
trigger peptide (Expected mass 646.3 Da, Experimental mass 646.3 Da). The double-conjugated Norb2-GGKGG
peptide is shown at left.

4.3 Results
4.3.1 Implementation and testing of the KNorb expression system using a superfolder GFP
(sfGFP) reporter.
The KNorb expression system was tested using a sfGFP150TAG reporter with a Cterminal hexahistidine tag. Successful amber suppression results in the expression of fulllength sfGFP that can be purified over a Ni2+-sepharose column. Conversely, failure of
the amber suppression system results in truncated proteins that lack a hexahistidine tag
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and are not purified over Ni2+-sepharose (Figure 4.6). sfGFP150K150 was expressed and
purified as described above. Purified sfGFP product was characterized by UV-Vis
spectroscopy and ESI-MS (Figure 4.6 a-c). Full-length sfGFP was obtained in good yield,
indicating successful KNorb incorporation.

Figure 4.6: Testing the KNorb
Expression System With a
sfGFP150TAG Reporter. (a) MS
Spectrum of sfGFP150K-His6
control. Expected mass: 27861.3
Da. Observed mass: 27862.8 Da.
(b) MS spectrum of
sfGFP150KNorb-His6. Expected
mass: 27997.5 Da. Observed mass:
27997.9 Da. (c) UV-Vis
absorbance of sfGFP150K-His6
control and sfGFP150KNorb-His6
both show peaks at 485nm,
coinciding with Amax of sfGFP. (d)
Purified sfGFP150K-His6 control,
yield: 12mg/L. (e) Purified
sfGFP150KNorb-His6, yield 3mg/L.

4.3.2 Testing the orthogonality of the FAz expression system.
Azidophenylalanine (FAz) is structurally similar to both phenylalanine and tyrosine. To
insure that the MjFazRS is truly orthogonal, BL21(DE3) cells were co-transformed with
pDule2CNF and psfGFP150TAG (encoding a sfGFP reporter with an amber codon at
150) and grown in noninducing medium (NIM) supplemented with ampicillin and
spectinomycin. After 12h, 100mL autoinducing medium (AIM) supplemented with
ampicillin and spectinomycin was inoculated with 1mL of the NIM starter culture and
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split into two 50mL batches. To the experimental batch (ncAA+) was added 1mM FAz
(nothing was added to the control batch (ncAA-)). After 24h, the experimental batch
exhibited a vivid yellow-green hue (Figure 4.7). The control batch did not exhibit
fluorescence. This indicates that the MjFazRS is orthogonal.

4.3.3 Reactivity of sfGFP150FAz with respect to strain-promoted azide-alkyne
cycloaddition (SPAAC).
To test for SPAAC reactivity, sfGFP150FAz was purified from a 50mL AIM culture and
incubated in PBS with a 2-kDa DBCO-PEG reagent. After 16h, SDS-PAGE of the
reaction mixture exhibited a significat shift in the sfGFP band with respect to an

Figure 4.7: Orthogonality of the FAz expression system and SPAAC reactivity of sfGFP150FAz. (A)
Induction of BL21(DE3) co-transformed with pDule2CNF and psfGFP150TAG yields fluorescence in
the presence of FAz (right) and no fluorescence in the absence of FAz. (B) Incubation of sfGFP150FAz
with a 2-kDa DBCO-PEG results in formation of the triazole cycloadduct.

unreacted control, thus confirming formation of the adduct.
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4.3.4 Expression and characterization of P22_T183KNorb, P22_T183FTet, and
P22_T183FAz nanocontainers.
Because mutations in the P22 coat protein can easily abolish self-assembly of the
procapsid, it is important to check each mutant for self-assembly. Expression and
purification of P22_T183KNorb, P22_T183FTet, and P22_T183FAz all resulted in
constructs that were permissive of self-assembly, as demonstrated by native agarose
electrophoresis, and that incorporated KNorb, FTet, or FAz, respectively, as confirmed by
ESI-MS (Figure 4.8-4.10). TEM micrographs of P22_T183KNorb revealed procapsids that
were indistinguishable from wild type. However, TEM micrographs of P22 T183FTet
revealed a significant degree of polydispersity relative to wild type (Figure 4.8C). TEM
micrographs of P22_T183FAz are currently underway.

Figure 4.8: Characterization of P22_T183KNorb nanocontainers. (A) ESI-MS spectrum of T183KNorb
coat protein (Expected mass [M + Na]+ 46764.2 Da, Experimental mass [M + Na]+ 46763.4 Da) indicates
expression of full-length coat protein with T183KNorb mutation. (B) Native agarose electrophoresis (1%,
65V, 2.5h) of P22GFP_T183K control (left lane) and P22GFP_T183KNorb (right lane, red circle)
confirms self-assembly of P22GFP_T183KNorb procapsids. (C) TEM micrograph of P22GFP_T183KNorb
procapsids (scale bar = 100nm).
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Figure 4.9: Characterization of P22_T183FTet nanocontainers. (A) ESI-MS spectrum of T183FTet
coat protein (Expected mass [M + Na]+ 46741.2 Da, Experimental mass [M + Na]+ 46738.9 Da)
indicates expression of full-length coat protein with T183FTet mutation. (B) Native agarose
electrophoresis (1%, 65V, 2.5h) of P22GFP_WT control (left lane) P22GFP_T183K control (center
lane), and P22MVIIA_T183FTet (right lane, red circle) confirms self-assembly of P22MVIIA_ T183FTet
procapsids. Note also that the upper band, corresponding to the expanded capsid conformation, is not
visible in the right lane. This suggests that the T183FTet mutation inhibits the rearrangement of the Adomain thought to be critical for capsid maturation. (C) TEM micrograph of P22MVIIA_T183FTet
procapsids (scale bar = 200nm).

Figure 4.10: Characterization of P22_T183FAz nanocontainers. (A) ESI-MS spectrum of T183FAz coat
protein (Expected mass [M + Na]+ 46683.1 Da, Experimental mass [M + Na]+ 46683.1 Da) indicates
expression of full-length coat protein with T183FAz mutation. (B) Native agarose electrophoresis (1%,
65V, 2.5h) of P22GFP_T183K control (left lane), P22_T183FAz crude (center lane) and P22_T183FAz
purified (right lane, red circle) confirms self-assembly of P22GFP_ T183FAz procapsids.

4.3.5 Initiation of iEDDA in P22_T183KNorb constructs.
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Incubation of P22GFP_ T183KNorb nanocontainers with Tet-GGKGG peptide resulted in
morphological distortion of the P22 constructs, as determined by native agarose
electrophoresis, DLS, and TEM (Figure 4.11) More specifically, treatment of
P22GFP_T183KNorb with 10x excess Tet-GGKGG resulted in a significant increase in
capsid diameter, as measured by DLS and native agarose electrophoresis. The increase in
diameter was accompanied by a striking change in capsid morphology, as indicated by
TEM characterization. These results indicate it may be possible to trigger P22
disassembly using iEDDA.

Figure 4.11: Morphological Effects of Tetrazine-GGKGG Treatment on P22T183KNorb capsids.
(A) Native agarose gel electrophoresis (1%, 65V, 2.5h) of P22_T183KNorb (Lane 1, control),
P22_T183KNorb treated with Grubbs II catalyst (Lane 2), and P22_T183KNorb treated with 10x excess
Tet-GGKGG (red circle). Treatment with Tet-GGKGG results in a morphological change, as indicated
by the band shift in Lane 3. (B) Dynamic Light Scattering (DLS) of P22WT capsids treated with TetGGKGG (left, control) versus P22_T183KNorb capsids treated with Tet-GGKGG. The P22WT capsids
exhibit a single peak with a hydrodynamic diameter of 68.1 ± 26.1nm. P22_T183K Norb capsids treated
with Tet-GGKGG exhibit two distinct populations: a peak of 68.06 ± 13.56nm, and a second peak of
531.2 ± 164.4nm. (C) TEM micrograph of P22_T183KNorb treated with Tet-GGKGG (scale bar =
200nm). Inset shows a TEM micrograph of untreated P22_T183KNorb constructs.

To better understand the stoichiometry of the reaction, P22GFP_ T183KNorb
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nanocontainers were incubated overnight with varying concentrations of the Tet-GGKGG
trigger peptide and standardized nanocontainer concentrations (Figure 4.12).
Morphological change as indicated by gel-shift assay was only observed for the highest
peptide concentration (6.5x mass excess). DLS analysis of P22GFP_ T183KNorb
nanocontainers likewise reveal a change in morphology after treatment, as indicated by
the appearance of a (dmean = 597.8 nm) peak that is not present in the control sample.
Finally, initiation of iEDDA with increasing concentrations of a Tet-GGKGG variant that
used hydro-tetrazine (1H-tetrazine) in lieu of methyl-tetrazine was carried out. Hydrotetrazine is less stable than methyl-tetrazine in water, but has faster kinetics under iEDDA.
Native agarose electrophoresis of the reaction products resulted in a weakening of the gel
band and streaking at high concentrations of 1H-Tet-GGKGG, which may be indicative
of capsid disintegration.
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Figure 4.12: Stoichiometry of iEDDA between P22_T183K Norb and Tet-GGKGG. (A) Treatment of P22_T183K Norb
with Tet-GGKGG peptide results in morphological changes only for high peptide concentrations (lane 7). DLS analysis of
treated (C) nanocontainers reveals a dmean = 597.8 nm peak that is not present in the untreated sample (B). The main peak
in both untreated (dmean = 55.9 nm) and treated (dmean = 55.5 nm) likely result from similar populations of unreacted
nanocontainers. (D) Treatment of P22_T183K Norb constructs with 1H-Tet-GGKGG results in a weakening of the gel band
and streaking at high peptide concentrations.

4.3.6 Initiation of iEDDA in P22_T183FTet constructs.
Incubation of P22GFP_ T183FTet nanocontainers with Norb-GGKGG peptide did not
produce any change in capsid morphology that could be detected by native agarose or
DLS.

4.3.7 Initiation of SPAAC in P22_T183FAz constructs.
It was noted above that incubation of a sfGFP150FAz reporter with a 2-kDa DBCO-PEG
resulted in cycloadduct formation, as determined by an SDS-PAGE gel-shift assay. This
experiment was repeated with assembled P22_T183FAz constructs: to 25ul of
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P22His6GFP_183FAz in PBS was added a 50x excess of 2-kDa DBCO-PEG at room
temperature. After 16h, native agarose electrophoresis revealed a significant gel shift in
the treated capsids, indicating formation of the cycloadduct (Figure 4.13).

Figure 4.13: (A) Native agaorse:
treatment of P22_T183FAz constructs
with DBCO-PEG P22_T183FAz
constructs treated with a 2-kDa DBCOPEG solution form a DBCO-PEG-P22
cycloaddiuct, as indicated by the band
shift in treated constructs (Lane 3)
relative to untreated constructs (Lane 2).
Lane 1 contains a P22GFP_WT control.
(B) SDS-PAGE: treatment of
P22_T183FTet crude extract with
sTCO-TAMRA. P22_T183FTet cultures
were flash centrifuged at 3700 rpm then
resuspended in PBS and treated with
2µL sTCO-TAMRA. After 5 m, sample
was spun down once more, resuspended
in SDS-PAGE loading buffer and
loaded onto a 10% SDS-PAGE gel.
Image at 583 nm, the emission λmax of
TAMRA, shows the conjugated coat
protein monomer in the treated sample
(lane 3) but not the control (lane 2),
indicating successful tetrazine-sTCO
conjugation.

4.3.8 Cytotoxicity of VLP constructs
To monitor cytotoxicity of the P22His6GFP and P22His6GFP_Norb constructs, an MTT assay
was carried out using BJ normal foreskin epithelial cells. No evidence of cytotoxicity was found
for treatment with VLP constructs at concentrations up to 100 µg/mL. (Figure 4.14)
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Figure 4.14: Cytotoxicity of P22 ncAA Constructs. MTT cytotoxicity assay in BJ normal human cells
indicates no significant cytotoxicity for any of the constructs tested (P22MVIIA_183FTet,
P22GFP_183KNorb, P22MVIIA_183KNorb, and P22GFP_WT control).

4.4. Chapter Conclusion
We have successfully constructed P22 nanocontainers with three distinct ncAAs (FAz, FTet
and KNorb) at the T183 site of the coat protein. Under native agarose electrophoresis, all
three of the mutants exhibited major bands corresponding to the major band of the wildtype procapsid intermediate. However, no band corresponding to the expanded
conformation was observed for any of the mutants, which suggests that the relatively
bulky ncAAs used here interfere with the rearrangement of the A-domain during capsid
maturation. While P22_T183KNorb are indistinguishable from P22 wild-type procapsids in
TEM micrographs, P22_T183FTet constructs exhibit a high degree of polydispersity
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relative to wild-type, which suggests that the bulky FTet residue interferes with selfassembly in addition to maturation.
Native agarose and DLS indicate morphological disruption and perhaps partial
disassembly for P22_T183KNorb constructs treated with high concentrations (10x mass
excess) of Tet-GGKGG and 1H-Tet-GGKGG peptides. Further investigation of the
iEDDA reaction at high concentrations of 1H-Tet-GGKGG is warranted to more fully
characterize this effect.
Incubation of P22His6GFP_183FAz constructs with DBCO-PEG resulted in formation
of the cycloadduct, accompanied by a significant change in capsid morphology, as
indicated by the band shift in native agarose electrophoresis. Additional study is needed
to further characterize this effect.
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Chapter 5: General Conclusion and Next Steps
5.1 General Conclusion
Venom peptides, which have been honed for specificity and potemcy by millennia of
evolution, are a promising source of novel therapeutic compounds. Prialt®, from the
Cone snail Conus magus, and Captopril®, from the Brazilian lancehead snake, are
examples of venom peptides that have become blockbuster drugs and led to paradigm
shifts in the treatment of pain and hypertension, respectively [4,153,154].
In addition, the development of solid-phase peptide synthesis (from the 1960s) and
recombinant gene expression (from the 1970s) has made it possible to synthesize
endogenous peptide hormones such as insulin, oxytocin, vasopressin, and
adrenocorticotrophic hormone (ACTH) on an industrial scale. Synthetic versions of these
peptide hormones are now essential compounds in the modern medical pharmacopeia [7].
In recent years, investigators have even used noncanonical amino acids to engineer
synthetic peptide analogs with sub-nanomolar dissociation constants [89].
Nevertheless, the pharmacokinetic limitations of most bioactive peptides—such as a
short plasma half-life, negative oral bioavailablity, and low membrane permeability—has
significantly curtailed their use [7,8]. A general system for the in vivo delivery of
bioactive peptides would help address these limitations.
This thesis project has explored the potential of viral-like particles (VLPs) derived
from the P22 bacteriophage procapsid to serve as a customizable peptide delivery vector.
In particular, the project has focused on two strategies for inducing the disassembly of
loaded P22-derived VLPs under physiological conditions: 1) a ring-opening metathesis

92

polymerization (ROMP)-based strategy, which aims to disrupt the architecture of a
functionalized capsid through the initiation of a living polymerization reaction, and 2) a
click-based strategy, which aims to mimic a destabilizing insertion mutation by clicking a
large macromolecule onto a functionalized handle located at a structurally sensitive site
in the capsid shell. The click-based strategy employed two bioorthogonal reactions: the
inverse electron-demand Diels-Alder cycloaddition (iEDDA) and strain-promoted azidealkyne cycloaddition (SPAAC).
Through the ROMP-based strategy, it was possible to construct functionalized
capsids, then induce capsid dissociation and trigger the release of a GFP cargo in PBS at
room temperature. This approach might be extended to photoactivated disassembly in the
future.
Using the iEDDA-based strategy, it was possible to construct P22-derived
nanocontainers with three different bioorthogonal handles at the senstive T183 site. The
three distinct bioorthogonal handles that were incorporated: azidophenylalanine (FAz),
tetrazinephenylalanine (FTet), and lysinenorbornene (KNorb). Furthermore, tetrazine- and
norbornen-functionalized peptides were synthesized for cross-reaction with
P22_T183KNorb and P22_T183FTet nanocontainers, respectively. While formation of the
cycloadduct was not observed for P22_T183FTet nanocontainers, reactions with
P22_T183KNorb and P22_T183FAz nanocontainers resulted in morphological changes to
the capsid. This approach might be extended to construct photolabile nanocontainers, as
described above.
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5.2 Next Steps
While this thesis has highlighted some of the opportunities for deliverying therapeutic
peptides using VLPs, much remains to be done. Currently, there is no silver bullet for the
delivery of peptide therapeutics to their molecular targets. As this work demonstrates,
there are many possible approaches to the problem. The 2015 FDA approval of Imlygic,
an oncolytic viral therapy for the treatment of melanoma, demonstrates the potential of
viral therapies, and suggests the viability of the VLP-based approach outlined here.
The disassembly strategies described in the preceding chapters rely upon exogenous
molecular triggers—a ruthenium catalyst in the case of the ROMP-based strategy, a
macromolecule with a biorthogonal handle in the case of the click-based strategy.
However, the use of exogenous triggers introduces complications, as the trigger must also
be transported to the delivery site, often in high concentrations. In addition, the trigger
needs to be non-toxic and inert with respect to common biological functional groups if it
is to be used in vivo. A delivery system that does not require an exogenous trigger is thus
desirable.
One approach is to use triggers that are not exogenous, but rather endemic to the
cellular environment of the target. This method was recently demonstrated for P22derived nanocontainers by the Feng Li group using cathepsin B, a lysosomal protease
overexpressed in many tumor cells. Fusion proteins consisting of the P22 coat protein
were joined to two cytotoxic peptides (the KLAK peptide and the NuBCP-9 peptide) by
cathepsin B cleavable linkers. P22-derived VLPs composed of the fusion protein
constructs were then introduced to MDA-MB-231 tumor cells, leading to cytotoxic
effects [142].
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The endemic trigger approach is an exciting development for peptide delivery to
environments in which such triggers can be identified. However, it is not completely
general. It would be useful to have a mechanism for inducing procapsid disassembly in
an arbitrary cellular environment.
One approach to induced disassembly in an arbitrary environment is to use light as a
trigger. Photoactivated disassembly would provide exquisite control over both delivery
site and drug dosage. It would also be relatively noninvasive, especially if it is possible to
use triggers that are photoactive at tissue-penetrating infrared or near-infrared
wavelengths. In what follows, we outline two strategies for photoactivated disassembly
of P22-derived nanocontainers.

5.3 Photoactivated ROMP Disassembly
Recent iterations of ROMP catalysts allow for photoactivated reactions that are initiated
when ROMP monomers are exposed to UV-visible light (~365–420 nm) in the presence of a
photolabile catalyst [67]. One recent study used light at similar wavelengths (380–500 nm) to
trigger a photoswitchable affinity tag targeting potassium channels in cultured cerebral cells.
Results from the same study indicated that brain tissue did not significantly impede light
penetration using 380–500 nm [143]. An alternative strategy for triggering a
photoactivated ROMP reaction within the CNS would be to use a red-shifted
photoswitchable catalyst, since near-IR radiation can more effectively penetrate tissue.
Photoactivated ROMP could thus provide a trigger mechanism for exerting precise
spatial and temporal control over the release of encapsulated drug cargoes.
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5.4 Photolabile Nanocontainers
A second strategy is to introduce photolabile instabilities, in the form of photocaged
noncanonical amino acids, at critical structural sites at the coat protein interfaces.
Exposure to light of the resonant wavelength would then activate the instabilities by
changing the chemical structure of the photolabile amino acid at the critical site. Capsid
disintegration and drug release would follow.
The genetic incorporation of photoactive amino acids has been extensively reported.
A representative selection is shown in Figure 5.1. Photocaged amino acids have been
used to activate a variety of cellular processes, including protein phosphorylation, DNA
transcription, and (perhaps inevitably) dsDNA cleavage via CRISPR-Cas9 [144–146]. A
photoisomerizable amino acid has also been incorporated through code expansion [147].

Figure 5.1: Genetically Encoded Photoactive ncAAs. (A) Photocaged lysine. (B) Photocaged
tyrosine. (C) Photocaged Cysteine. (D) Photoisomerizable ncAA. (E) ncAA that induces photocleavage
of the peptide backbone.

The incorporation of a photocaged noncanonical amino acid (PncAA) at a critical
structural site is expected to abolish self-assembly by disrupting the noncovalent
interactions between coat protein monomers. However, it may be possible to identify
“compensating” mutations (corresponding to changes in the complementary region of the
adjacent monomer, see Figure 5.2) that rescue self-assembly through directed evolution
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methods. In addition, because the P22 procapsid is composed of 420 identical copies of
the coat protein monomer, all mutations would be targeted to a single gene.

Figure 5.2: Compensating mutations. A hexagonal tiling of the plane (left) corresponds to the 2dimensional surface of the icosahedral capsid. A modified tile shape that preseves the underlying
symmetry (right) is produced by introducing a compensating change for each modification of the
asymmetric unit.

The choice of the PncAA insertion site (and the complementary randomization
region) would be guided by a consideration of the structural properties of the P22
procapsid. For instance, charged residues at the tip of the coat protein D loop are known
to stabilize the procapsid shell through interactions with oppositely charged residues in
the ED and P domains of the adjacent coat protein monomer. In addition, there are seven
temperature-sensitive mutation sites associated with noncovalent interactions between
coat protein monomers: W48, P238, T258, S262, M267, F353, and Y411 [45].
As noted above, incorporation of the PncAA is expected to break self-assembly. To
identify rescue mutants, a coat protein library consisting of the PncAA at the critical site
and a randomized sequence in the complementary region will be generated, expressed,
and subjected to negative selection to eliminate mutants that do not self-assemble.
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Randomization will target five or six residues in the complementary region, for a library
size in the 106 – 108 range. Similar directed evolution methods have been used to increase
the loading capacity and stability of protein nanocages [148,149].There are two possible
selection strategies in the present case: in-cell selection and cell-free selection.
In-cell selection would use the encapsulation of a toxic gene product (such as the
barnase endonuclease) as the basis for selection. For instance, a barnase-scaffold fusion
protein could be co-expressed with coat protein mutants from the library. Mutants that
rescue self-assembly would sequester the barnase-scaffold protein in procapsids, leading
to colony survival. Mutants that are incapable of self-assembly would be flooded with
toxic barnase, leading to cell death and elimination from the library. Selected mutants
could be sequenced and characterized. The in-cell selection could be fine-tuned by
placing the coat protein mutant and barnase-scaffold protein under the control of distinct
promoters, such as a lactose-inducible T7 promoter and an arabinose-inducible AraC
promoter. De-coupling expression of the coat protein and barnase-scaffold fusion would
make it possible to build up a buffer of coat protein monomers prior to induction of the
toxic barnase-scaffold fusion. Differential induction of the P22 coat protein and P22
scaffold protein has been reported by Qazi et al. (2016) [21].
Cell-free selection would use either size-exclusion chromatography or
ultracentrifugation to select for assembled capsids on the basis of physical and structural
properties. This is expected to be straightforward. The primary difficulty would be
recovery of the coat protein sequence from assembled procapsids. That is to say, the
problem is recovery of the genotype from the phenotype. In other library-based selection
methods, such as phage display or mRNA display, recovery of the genotype (the mRNA
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that codes for the phage coat or nascent peptide) is facilitated by physically linking it to
the phenotype (the phage coat or the nascent peptide) [150,151]. Encapsulation of the
coat protein mRNA might be accomplished by fusing an RNA aptamer to the 5’-end of
the coat protein mRNA, and the small peptide to which the aptamer binds to the Nterminal of the coat protein, as illustrated in Figure 5.3 [152]. Recovery of the genotype
would be accomplished through treatment with TRIzol, reverse transcription, and PCR
amplification.

Figure 5.3: RNA-directed packaging of a protein cargo in bacteriophage Qβ. An RNA aptamer (αRev) developed for its capacity to bind an arginine-rich peptide (Rev-tag) is fused to the 5’-end of an
mRNA. A 3’-hairpin binds to the interior surface of the capsid. The Rev-tag that binds to the α-Rev
aptamer is incorporated at the N-terminal of the cargo protein. From Fiedler et al.
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